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Abstract
Cholesterol crystals have been linked to activation of the NLRP3
inflammasome and the formation of foreign body giant cells (FBGCs). It
has been hypothesized that FBGCs have a role in advanced atherosclerotic
plaque formation. This thesis examined the feasibility of producing
stable cultures of FBGCs starting with human monocytes with the
goal to examine pterin production by these cells in comparison to
human monocyte derived macrophages (HMDMs). The study also
investigated the effect of cholesterol crystals on 7,8-dihydroneopterin
(7,8-NP) production and modulation of IL-1  levels in macrophages.
7,8-Dihydroneopterin is a potent antioxidant generated by macrophages
which also down regulates the expression of macrophage scavenger
receptor CD36. The use of alpha-tocopherol and IL-4 as FBGC fusion
mediators was explored. Using these mediators, large numbers of
FBGC were successfully cultured. The rates of fusion achieved in the
cultures were low, and the cells had poor adhesion, which prevented
pterin measurement. FBGC, which are thought to remove crystallized
cholesterol from the plaque, cleared 21% of cholesterol crystal compared
to 50% cleared by HMDM cells. Due to this result, the effect of
cholesterol crystals on pterin production in monocytes and macrophages
was explored. Cholesterol crystals cause inflammation through the
activation of the NLRP3 inflammasome, however, it was unknown
whether they could modulate 7,8-NP production. Cholesterol crystals
caused an intracellular dose-dependent loss of 7,8-NP to its oxidized form,
neopterin, in HMDM cells. Cholesterol crystals induced intracellular
synthesis of 7,8-NP in HMDMs. 7,8-NP was released into the supernatant
and oxidized to neopterin in media. Monocytes treated with cholesterol
crystals released up to 100 nM of neopterin and 120 nM of 7,8-NP in
the media after 48 hours. The combination of IFN- and cholesterol
crystals appeared to inhibit the release of 7,8-NP into the media for the
first 48 hours, after this time 7,8-NP release rapidly increased. The
addition of exogenous 200 µM 7,8-NP showed that in the presence of
monocytes, cholesterol crystals did not cause the oxidation of 7,8-NP to
neopterin, as seen in HMDMs but possibly to 7,8-dihydroxanthopterin
or xanthopterin. The presence of 7,8-NP increased IL-1  expression in
the presence of cholesterol crystals after 24 hours incubation. FBGCs
and the removal of cholesterol crystals may be a key process in the
resolution of atherosclerotic plaques. It appears that cholesterol crystals
are able to modulate inflammatory processes including activation of
the inflammasome and balance of 7,8-dihydroneopterin to the oxidized
neopterin. The infiltrating monocytes may provide antioxidant protection
against the inflammation induced by cholesterol crystals and the activity
of the infammasome.
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1Introduction
1.1 Overview
Atherosclerosis is a complex and multifaceted disease that affects millions of people
worldwide. Many aspects of the disease and its pathogenesis have been studied in
detail. Recently, however, there has been growing evidence of an inflammatory role
played by cholesterol crystals in atherosclerotic plaques. It is thought that the presence
of cholesterol crystals initiates an inflammatory response known as the foreign body
response (FBR). The FBR causes the development of infiltrating monocytes and
macrophages into much larger cells called giant cells. Giant cells are thought to
be able to remove chronic inflammatory stimuli such as cholesterol crystals through
phagocytosis. Cholesterol crystals have also been shown to induce inflammation
through the activation of the NOD-like receptor family, pyrin domain containing
3 (NLRP3) inflammasome, a protein complex which initiates the cleavage of the
inactive form of interleukin-1 beta (IL-1 ) to its active form. IL-1  is thought to
be proinflammatory and proatherogenic in its nature.
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1.2 Foreign Body Response
The FBR is an end-stage innate inflammatory response evoked when a cell encounters
an object that it determines to be non-self. This response leads to the influx of
macrophages at the site and the formation of giant cells (van Putten et al., 2009).
Recently it has been discovered that this process initiates an inflammatory response
involving the activation of the intracellular NLRP3 inflammasome (Malik et al., 2011).
Endogenous crystalline material such as cholesterol crystals, as well as, exogenous
material such as bioimplants have been shown to cause the foreign body response
(Nair et al., 1998).
The FBR is categorized by three stages: onset, progression and resolution. The
FBR occurs after an initial acute inflammatory response (Anderson et al., 2008;
Kyriakides and Bornstein, 2003). If the inflammation fails to resolve because of the
presence of a foreign object then a full scale FBR occurs. The onset of this response
requires the cell to determine that a non-self object is present. This process is not
yet fully understood. It is thought that the cell may recognize a layer of adsorbed
proteins (Shen et al., 2004). Adsorbed proteins are soluble proteins that have collected
on the surface of the object. The specific collection of proteins, charged ions and
polarizable molecules that deposit on the surface of the object is dependent on the
chemical and physical properties of the foreign body (Hu et al., 2001; Shen and
Horbett, 2001; Thull, 2002). The onset of the foreign body response is characterized
by the initiation of chemoattractants that cause the arrival of neutrophils, monocytes
and macrophages to the site of inflammation (Luttikhuizen et al., 2006). Once the
FBR begins, it progresses into a chronic inflammatory response. Foreign objects that
are too large for macrophages to absorb cause the formation of giant cells. As soon
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as the particle has been degraded the giant cells disappear, suggesting that their role
is specifically focused on larger particles. The FBR response begins to resolve once
the foreign body has been removed. At this stage the production of TGF  is increased
(Li et al., 2007). The increase in TGF  levels suppresses the production and secretion
of chemoattractants which stops the influx of inflammatory cells (Luttikhuizen et al.,
2006). Finally, macrophages leave the site and progress to the draining lymph nodes
(Bellingan et al., 1996).
1.3 Role of FBR in Atherosclerosis
The foreign body response is relevant to many inflammatory conditions. However,
almost no research exists into how the foreign body response pertains to cholesterol
crystals found in atherosclerotic plaques. Foreign body giant cells have been shown to
be prevalent in mice on a high fat diet (Samokhin et al., 2010). Cholesterol containing
foreign-body giant cells have been found in the aortic wall of rabbits (Bjorkerud and
Bondjers, 1973).
Atherosclerosis affects a growing percentage of the world’s population. Currently,
30.6% of all deaths are caused by cardiovascular disease (Roger et al., 2012).
This reflects the changes in diet and lifestyle in first world nations, where obesity
is becoming increasingly common. Atherosclerosis is a complex disease; its
pathogenesis and causes are still largely unclear even after several decades of research.
A combination of genetic and environmental risk factors influence the development
of atherosclerosis. The main factors thought to be influencing the progression of
atherosclerosis are: elevated low density lipoprotein (LDL) and very low density
lipoprotein (VLDL) levels, smoking, and a high fat diet (Dos Santos et al., 2008).
3
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There is much overlap between atherosclerosis and other chronic inflammatory
diseases such as arthritis and type I diabetes. An interesting development is the
discovery of the inflammasome complexes, which may explain the link between a
number of these inflammatory conditions (De Nardo and Latz, 2011).
To date, several hypotheses have been put forward to explain the initial events
that trigger the development of a healthy artery into a fatty streak, and later on,
into an atherosclerotic plaque. These include the oxidative modification hypothesis
and the response-to-injury hypothesis. The oxidative modification hypothesis hinges
on the uptake of oxidized low density lipoprotein (oxLDL) by scavenger receptors
causing foam cell formation, which are found in fatty streaks. The response-to-injury
hypothesis suggests that injury of some form (mechanical or infectious) results in the
infiltration of monocytes (Bobryshev, 2006), which differentiate into macrophages.
These macrophages then take up lipids and become the foam cells found in fatty
streaks.
It has been known for over 60 years that cholesterol crystals are present in plaques
(Flory, 1945). Cholesterol crystals are most likely to cause chronic inflammation in an
atherosclerotic plaque rather than triggering the initial acute inflammatory response
that is seen with oxLDL. Cholesterol crystal deposits, in the form of clefts, have
been found in areas near the lipid-rich core in histological plaque sections (Bocan
et al., 1986). The crystal deposit is dissolved by the use of ethanol during tissue
fixation. Initially, it was thought that these deposits were inert and not involved in
the inflammation associated with atherosclerosis. It has only recently been discovered
how these crystals induce inflammation in plaques (De Nardo and Latz, 2011; Duewell
et al., 2010; Freigang et al., 2011; Rajama¨ki et al., 2010). Research is currently moving
towards being able to selectively identify cholesterol crystals in atherosclerotic plaques
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using the latest image scanning technology (Suhalim et al., 2012).
Recent research has led to the suggestion that cholesterol crystals may be involved
in the weakening of the fibrous cap, which in turn can cause plaque rupture.
Cholesterol crystals expand as they form and pierce through the plaque (Vedre et al.,
2009). When exposed to blood, cholesterol crystals form emboli that have been
shown to block blood vessels and arteries (Moolenaar and Lamers, 1996). This type
of embolism is rare but most often occurs after procedures such as angiography or
vascular surgery.
1.4 Giant Cells
1.4.1 Multinucleated Giant Cells
The foreign body response induces the formation of giant cells. Giant cells are
formed, not by cell division, but by the fusion of many monocytes and macrophages
(Murch et al., 1982), hence they are often termed multinucleated giant cells (MGCs).
MGCs are found in both infectious and inflammatory conditions. These conditions
include AIDS (Botticelli et al., 1989), sarcoidosis (Okamoto et al., 2003b), bone
tumors (Joyner et al., 1992), giant cell arteritis (Ly et al., 2010), Crohn’s disease (Liu
et al., 1996) and atherosclerosis (Samokhin et al., 2010). The classification of MGC
covers several different morphologies of giant cells, each with a specific phenotype
and function. The most common types of giant cells are: Langhans’ giant cell (LGC),
Touton’s giant cell, the osteoclast, and the foreign body giant cell (FBGC).
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1.4.1.1 Langhans’ Giant Cells
MGCs were identified by Theodor Langhans in 1868 (Pritchard et al., 2003).
Langhans’ giant cells are typically found in granulomas and infected tissue. They
model a type I interferon-gamma (IFN- )-dependent immune response and primarily
deal with the removal of microbial pathogens. Langhans’ giant cells are particularly
common in Mycobacterium tuberculosis granulomas, where they prevent the spread
of the mycobacterium to other healthy tissue by secluding it (Lay et al., 2007). The
Langhans’ cells are distinctive as the nuclei form a horseshoe shape inside the cell.
Okamoto et al. (2003a) found a typical cell contains between 3 and 11 nuclei.
1.4.1.2 Touton’s Giant Cells
Fusion of cells to form Touton’s giant cells is induced by IFN-  (Schepetkin et al.,
2001). Touton’s giant cells are thought to develop from foam-like cells (Watanabe
et al., 1982). Foam-like cells have a high lipid content due to the sequestering
of aggregated or oxidized lipoproteins. Touton’s giant cells have a much higher
lipid content in their cytoplasm than other giant cells. This lipid-laden cytoplasm is
encircled by the nuclei. The presence of these cells, particularly in cases of fat necrosis
and xanthogranulomas, is well documented (Aterman et al., 1988; Drummond et al.,
2001; Janney et al., 1991; Provenzano et al., 2010). However, very little is actually
known about the formation and function of the Touton’s giant cell.
1.4.1.3 Osteoclasts
Osteoclasts are specifically involved in calcium resorption, that is, the process of
releasing calcium from bones into the bloodstream (Bradley and Oursler, 2008). The
6
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osteoclast cell membrane is ruffled in order to increase surface area for calcium
resorption. These cells derive specifically from bone marrow macrophages. A typical
osteoclast contains around 9 nuclei which are closely associated with one another
(Jaworski et al., 1981). Osteoclast formation is induced by receptor activator of nuclear
factor kappa-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF)
(Kreja et al., 2007).
1.4.1.4 Foreign Body Giant Cells
FBGC form in the presence of asbestos particles (Sethi et al., 1974), silica (Prieditis
and Adamson, 1996), monosodium urate (MSU) crystals (Bhadani et al., 2006) and
cholesterol crystals (Nair et al., 1998). FBGC are the largest of the giant cells and
contain up to 100 nuclei (Enelow et al., 1992). The arrangement of nuclei in FBGCs is
non-uniform. These cells are distinct from Langhans’ and Touton’s giant cells as they
form upon stimulation with interleukin-4 (IL-4) or interleukin-13 (IL-13) (McNally
and Anderson, 2011; Miyamoto et al., 2012). This giant cell phenotype is most
commonly associated with the foreign body response. Historically, the process of
FBGC formation was not well understood. However, recent advances in the field have
provided a much clearer picture of the molecules and signalling involved in FBGC
fusion.
1.4.2 Formation of Foreign Body Giant Cells
The fusion of macrophages and monocytes to form foreign body giant cells is a three
stage process. The adhesion, recognition and fusion of cells requires a number of
specific mediators and is tightly regulated.
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1.4.2.1 Adhesion
Adhesion is a requirement for giant cell fusion. It has been found that cell membrane
bound  -integrins bind to vitronectin, an adhesion glycoprotein found in serum.
This binding initiates cellular attachment (Brodbeck and Anderson, 2009; Helming
and Gordon, 2009). Cellular attachment requires multiple complex interactions
and several other proteins have been implicated in this process. Both dentritic
cell specific transmembrane protein (DC-STAMP) and E-cadherin, membrane-bound
glycoproteins, are required for giant cell formation to occur (Martinez and Helming,
2009; Moreno et al., 2007). The transcription of both of these proteins is controlled
through cytokine signaling. Interleukin-4 binds to the janus kinase 1 (JAK1) receptor.
The cytoplasmic domain of the transmembrane receptor is then phosphorylated
(Murray, 2007). This initiates the recruitment and activation of the signal transducer
and activator of transcription 6 (STAT6) monomer (Gooch et al., 2002). The active
monomer then dimerizes. The STAT6 dimer is a transcription factor and induces
the transcription of DC-STAMP and E-cadherin. This activation of the JAK/STAT
pathway also has implications in the function of giant cells.
1.4.2.2 Recognition
For fusion to occur, cellular recognition must take place. After adhering, cells begin
to protrude lamellipodia (Jay et al., 2007), a cytoskeletal projection containing actin
found on the leading edge of the cell (Ballestrem et al., 2000). These lamellipodia
have been shown to contain high levels of intracellular and membrane bound cluster
of differentiation 36 (CD36) receptors. It is thought that cellular recognition occurs
through the binding of phosphatidylserine (PS) on the surface of one cell to the
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scavenger receptor CD36 present on the surface of another cell (Helming et al., 2009).
In order for PS to be present on the cell surface, flipping must occur. Normally, PS is
located in the lipid bilayer of the cellular membrane. However, it has been shown that
alpha-tocopherol (↵-TocH) can induce PS flipping (Klein et al., 2006). PS flipping
also occurs in apoptotic cells (Fadok et al., 1998). Additional fusion receptors such
as CD44, CD47, CD54 and CD200 (Chen and Olson, 2005; Quinn and Schepetkin,
2009) indicate that the cell is not in apoptosis. Instead, a fusion process similar to, but
distinct from phagocytosis is initiated (McNally and Anderson, 2005).
1.4.2.3 Fusion
Once the target cell has been identified, fusion can occur. The method of giant cell
fusion is still not fully understood. It is thought that mannose receptors (MRs) are
involved in giant cell fusion as they are found to be clustered at fusion interfaces
(McNally and Anderson, 2011). The MR recognizes carbohydrates on glycoproteins.
This recognition generally leads to the endocytosis of the proteins. However, in the
case of giant cells, it is hypothesized that this recognition leads to the engulfment
of an entire cell. Several other proteins and receptors are thought to be involved.
The purinergic receptor (P2X7) receptor which is an adenosine triphosphate (ATP)
gated ion channel that forms a membrane pore, is involved in both the macrophage
fusion process (Lemaire et al., 2006) and inflammasome activation (Miller et al.,
2011). Blocking either CD47 or signal-regulatory protein alpha (SIRP-↵), both
membrane proteins that interact with one another during cell-cell adhesion (Babic
et al., 2000), prevents macrophage fusion (Han et al., 2000). A chemokine, monocyte
chemoattractant protein-1 (MCP-1), is also thought to be involved in the fusion process
through interactions with DC-STAMP (Low et al., 2001). This chemokine has also
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been implicated in both early and advanced plaque formation (Boyle, 2005).
1.5 Cholesterol Crystals
Cholesterol crystals are often surrounded by giant cells (Flory, 1945; Moolenaar
and Lamers, 1996), which has lead to the suggestion that the crystals induced
multinucleated cell formation. Usually, cholesterol plays an important role in
maintaining the viscosity of cell membranes and is a precursor molecule to steroid
hormones.
Cholesterol crystals form in aqueous solutions due the low solubility of cholesterol
(De Nardo and Latz, 2011). For crystallization to occur there must be a nucleating
stimulus. Crystallization most commonly occurs in areas of high free lipid content,
for example, the necrotic core or in macrophage foam cells. Cholesterol crystals have
been found in the necrotic core in atherosclerotic lesions of apolipoprotein E (ApoE)
deficient mice (Freigang et al., 2011). Geng et al. (2003) have shown that lipid-laden
macrophages produce cholesterol crystals at 37  C but raising the temperature to 40  C
inhibits this ability. It has been found that cholesterol crystals can grow to 120 µM in
synovial fluid (Zakharova et al., 2009).
It appears that there are two processes leading towards the formation of cholesterol
crystals in the atherosclerotic plaque. The first is the formation of crystals inside a
cell, e.g. a lipid-laden macrophage. The second is formation due to the death of cells
and the release of free cholesterol. These crystals form acellularly, most commonly
in the necrotic core of the atherosclerotic plaque. The first type of cholesterol crystal
is generally needle-shaped, and if the crystals become large enough, can be released
from the macrophage (Geng et al., 2003). Intracellular cholesterol crystal formation is
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thought to be initiated rapidly after the oxidation of cholesterol. It appears that these
macrophages are resistant to apoptosis, which is thought to add to the plaque instability.
The cholesterol crystals formed in the necrotic core are much more rhomboidal and
planar (Flory, 1945).
1.6 NLRP3 Inflammasome
Foreign bodies, such as cholesterol crystals, can be recognized as danger-associated
molecular patterns (DAMPs) by NOD-like receptor (NLR). This leads to the activation
of the NLRP3 inflammasome, a high molecular weight protein complex. NLRs
are intracellular receptors that have been compared in function to the extracellular
toll-like receptor (TLR), which are known to have a role in recognizing microbial
pathogen-associated molecular patterns (PAMPs) (Hansson and Libby, 2006).
A basic subunit of the NLRP3 inflammasome contains NLRP3,
apoptosis-associated speck-like protein (ASC), and caspase-1 (see Figure 1.1).
Under non-inflammatory conditions, these proteins are expressed but internal
auto-repression prevents their activation (Tschopp and Schroder, 2010). Currently
there are three proposed models of activation of the inflammasome: the channel
model, the lysosomal rupture model and the reactive oxygen species (ROS) model.
The channel model suggests that the efflux of K+ induces the formation of a
P2X7-pannexin 1 pore which allows the influx of extracellular factors, such as PAMPs
and DAMPs that activate NLRP3 (Pe´trilli et al., 2007). In the lysosomal rupture
model, phagocytosis of PAMPs and DAMPs cause lysosomal damage. This in turn
leads to the release of cathepsin B, a protease, which induces the activation of NLRP3
through an unknown mechanism (Hornung et al., 2008). Finally, the ROS model
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proposes that the phagocytosis of PAMPs and DAMPs induces ROS production. ROS
production causes the release of thioredoxin-interacting protein (TXNIP), an NLRP3
activating ligand, from its inhibitor, thioredoxin (TRX). The current view of NLRP3
inflammasome activation is that the mechanisms listed above are not necessarily
mutually exclusive and that each may play a part in the activation process.
Upon activation, NLRP3 migrates from the endoplasmic reticulum (ER)
and recruits ASC, which migrates from the cytoplasm (Zhou et al., 2011).
Subunit oligomerization occurs in the perinuclear space through the interaction of
CARD-CARD and PSY-PSY domains which are located on the ASC and NLRP3
respectively (Martinon et al., 2009). When the inflammasome is fully formed it
contains 7 subunits and is approximately 2 µm in diameter (Figure 1.2). Based on the
size of the complex, it is not surprising to find that only one NLRP3 inflammasome
forms per cell. To put this in context, a whole cellular organelle such as the
mitochondrion is only 1 µm in diameter.
The function of the inflammasome is to activate inflammatory caspases. The
NLRP3 inflammasome activates caspase-1, a cysteine protease, which induces the
cleavage of proIL-1  to IL-1 ; the biologically active form. However, activation of
the NLRP3 inflammasome alone is not enough to induce the production of mature
IL-1 . Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B), a DNA
transcription factor, must also be activated (see Figure 1.3). Priming of the cell occurs
by a signal cascade resulting from the recognition of PAMPs by TLRs. It has been
shown that significant IL-1  production occurs in the presence of a stimuli, such as
cholesterol crystals or alum, if cells have been primed with lipopolysaccharide (LPS);
an known endotoxin (De Nardo and Latz, 2011; Franchi and Nun˜ez, 2008). However,
without this priming, only a low level of IL-1  is produced.
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Figure 1.1: A subunit of the NLRP3 inflammasome - The basic unit of the NLRP3
inflammasome consists of a NLRP3 domain bound to the adaptor protein ASC and
caspase-1. Figure adapted from Martinon et al. (2009)
Figure 1.2: The NLRP3 inflammasome converts proIL-1  to IL-1  - Activation
of caspase-1, the enzyme responsible for the cleavage of proIL-1 , requires the
oligomerization of the NLRP3 subunits. IL-1  processing is thought to occur through
the central pore in the inflammasome. Figure adapted from Martinon et al. (2009)
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Figure 1.3: Process of NLRP3 inflammasome activation - Cholesterol crystals activate
the NLRP3 inflammasome through processes including potassium efflux, lysosomal
damage and production of ROS.
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1.7 Interleukin-1 
Interleukin-1  is a cytokine from the interleukin-1 family. It is produced in a number
of cells including monocytes, smooth muscle cells (SMC) (Wang et al., 1995), and
endothelial cells (Strieter et al., 1989). Transcriptional activation of IL-1  is typically
induced by the presence of LPS (Grahames et al., 1999). Monocytes are capable of
producing large quantities of IL-1  messenger ribonucleic acid (mRNA), although,
only a small proportion of the mRNA is translated into protein, as there is a dissociation
between the transcription and the translation of IL-1  (Schindler et al., 1990). The
mRNA transcript is stable for at least 24 hours after being produced. It is during this
time that it can be transported to the site of translation. IL-1  is synthesized in an
inactive form, proIL-1 . Monocytic cells are able to process proIL1-  and secrete it
in its mature form.
Rajama¨ki et al. (2010) have shown that cholesterol crystals induce a
dose-dependent release of IL-1  from both monocytes and macrophages. Interestingly,
in primary cells this response required two stimuli, the cholesterol crystals and the
additional stimulus LPS. LPS is a large molecule that is found in the outer membrane
of gram-negative bacteria. As an endotoxin, it induces a strong immune response.
However, in the monocyte-like cell line THP-1 the response could be achieved with
out the presence of LPS. This response was found to be caspase-1 dependent, as there
was found to be no IL-1  when caspase-1 was blocked.
IL-1  is thought to be proinflammatory and proatherogenic. It has been shown
to upregulate cyclooxygenase (COX)-2, a key enzyme in prostaglandin synthesis
(Colville-Nash and Gilroy, 2001), in smooth muscle cells (Yang et al., 2002). COX is
a common target for nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin
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and ibuprofen. Patients with atherosclerosis in their coronary artery have been found to
have higher levels of IL-1  that correlate with the disease severity (Galea et al., 1996).
1.8 Neopterin and 7,8-Dihydroneopterin
Neopterin is commonly used as a clinical marker of inflammation in urine and serum
samples (Fuchs et al., 1993). Increased neopterin levels have been associated with
increased atherosclerosis in patients (Tatzber et al., 1991; Weiss et al., 1999).
7,8-Dihydroneopterin, a precursor to neopterin, is synthesized by monocytes (Seki
et al., 1996), macrophages (Sghiri et al., 2005) and giant cells (Shaskan et al., 1992),
each to a different extent. 7,8-dihydroneopterin (7,8-NP) is produced by the conversion
of guanine triphosphate (GTP) to 7,8-dihydroneopterin triphosphate (7,8-NP-PPP) by
guanine triphosphate cyclohydrolase 1 (GTPCH-1) (see Figure 1.4). The phosphates
are then removed by non-specific phosphatases. The 7,8-NP can then be further
converted to neopterin by oxidation.
It has been proposed that 7,8-NP has an antioxidant role in vivo (Gieseg
et al., 1995). Studies by Gieseg et al. (2001) have shown that 7,8-NP is able to
protect monocyte-like U937 cells from cell death caused by oxLDL toxicity. It is
thought that this protection is due to the scavenging of lipid peroxyl radicals by
7,8-NP. Interestingly, ↵-TocH also acts as an antioxidant and free radical scavenger
(Brigelius-Flohe´, 2009), as well as inducing giant cell formation. This scavenging of
radicals prevents damage to the cell and the loss of glutathione (GSH), which is a key
event in oxLDL triggered cell death (Baird et al., 2005). 7,8-NP has also been shown
to downregulate CD36 (Gieseg et al., 2010). This downregulation limits the uptake
of oxLDL which prevents foam cell formation and cell death. It is unknown whether
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this downregulation of CD36 by 7,8-NP has any involvement in preventing giant cell
formation.
In most cell types there is very little neopterin or 7,8-NP present as the majority of
7,8-NP-PPP is converted into tetrahydrobiopterin (BH4) and its derivatives. BH4 is a
cofactor for nitric oxide synthase (NOS), which produces nitric oxide (NO) (Maier
et al., 2000) and is also largely involved in the biosynthesis of neurotransmitters
(Habecker et al., 2002). However, in monocytes and macrophages, neopterin and
7,8-NP build up due to a low level of active 6-pyruvoyl tetrahydropterin synthase
(PTPS) (Leitner et al., 2003). PTPS is responsible for the downstream processing
of 7,8-NP-PPP to BH4. Transcription of the PTPS mRNA is upregulated by IL-1 .
This suggests that IL-1  may have a role in determining the balance of 7,8-NP and
BH4 present in a cell.
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Figure 1.4: Biosynthesis of 7,8-NP and Neopterin - GTP is converted to
7,8-dihydroneopterin triphosphate (7,8-NP-PPP) by the enzyme GTP cyclohydrolase I.
7,8-NP-PPP can then either be converted to 7,8-dihydroneopterin (7,8-NP) by non-specific
phosphatases, or to tetrahydrobiopterin through 6-pyruvoyl-tetrahydropterin synthase
(PTPS) and sepiapterin reductase (SR). Oxidation of 7,8-NP results in the formation of
neopterin.
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1.9 Clinical Targets: Cholesterol Crystals and the
Inflammasome in Atherosclerosis
It was thought that the formation of cholesterol crystals in the plaque was a late event
in the disease progression. However, confocal microscopy techniques have shown that
cholesterol crystal formation coincides with monocyte infiltration, which is an early
event in plaque formation (Duewell et al., 2010). Blocking phagocytosis of cholesterol
crystals prevented the activation of the NLRP3 inflammasome. Freigang et al. (2011)
proposed the idea that cholesterol crystals and the NLRP3 inflammasome are linked
to oxidative stress via NF-E2-related 2 (Nrf-2) signalling. Nrf-2 is known to limit the
effects of oxidative stress by inducing the expression of antioxidant enzymes. Nrf-2 is
required for NLRP3 activation by cholesterol crystals. It is thought that this activation
of the inflammasome explains why increased Nrf-2 has been shown to aggravate
atherosclerosis. Whilst there may be less oxidative stress, cholesterol crystals may
promote chronic inflammation in the atherosclerotic plaque.
A key target currently is developing methods that allow for the early detection
of atherosclerosis. Current technologies available are either too invasive (surgery) or
of too low quality (ultrasound) to view the development of atherosclerotic plaques.
Cholesterol crystals may provide a way of measuring plaque development. The
crystals form in early plaques and may be visualized using multispectral CT imaging
technology, though this technology is still very much in the prototype phase of
development (personal communications). Early detection would allow for better
prevention of atherosclerosis and intervention if necessary.
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1.10 Research Programme
This thesis aims to examine the inflammatory response of giant cells to a cholesterol
crystal stimulus. This will be studied by developing a giant cell culture system and then
examining neopterin and 7,8-NP production after incubation with cholesterol crystals
by high performance liquid chromatography (HPLC).
The interaction between giant cells and cholesterol crystals is hypothesized to
result in higher 7,8-NP and neopterin production in giant cells than macrophages. In
Chapter 3 the feasibility of a giant cell culture system that is comparable to cultured
HMDMs is examined. This chapter investigates the fusion mediators required for giant
cell formation, attempts to quantify giant cells in culture and measure their viability
using common assays.
Having established a giant cell culture, it was intended that neopterin and 7,8-NP
production would be measured by HPLC. Unfortunately, experiments carried out in
Chapter 3 showed that giant cell culture is highly variable and does not produce
replicable results. Instead, in Chapter 4 the effect of cholesterol crystals on neopterin
and 7,8-NP production will be investigated in monocytes and macrophages, both
precursors to giant cells. This chapter will also examine the effect of cholesterol
crystals on IL-1  production and possible modulation by 7,8-NP.
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2.1 Materials
2.1.1 Reagents
All reagents used were of analytical grade or better. All solutions were prepared
using ion-exchanged ultra filtered water, produced using a Milli-Q integral water
purification system from Millipore (Massachusetts, USA).
↵-Tocopherol (↵-TocH) Sigma Chemical Co., MO, USA
3-[4,5-Dimethylthiazol-2-yl]-2,5
-diphenyl-tetrazolium bromide (MTT) Sigma Chemical Co., MO, USA
7,8-Dihydroneopterin (7,8-NP) Schircks Laboratory, Switzerland
Acetic acid (glacial) Scharlau Chemie S.A., Barcelona, Spain
Acetonitrile (ACN) J.T. Baker, NJ, USA
Ammonium chloride (NH4Cl) May & Baker Ltd, Dagenham, England
Ammonium phosphate dibasic ((NH4)2HPO4) Sigma Chemical Co., MO, USA
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Ascorbic acid Sigma Chemical Co., MO, USA
Cholesterol Sigma Chemical Co., MO, USA
Citrate Sigma Chemical Co., MO, USA
Ethylene-diamine-tetra-acetic acid (EDTA) Sigma Chemical Co., MO, USA
Ethanol BDH Lab Supplies Ltd, Poole, England
Granulocyte-macrophage colony- Bayer HealthCare Pharmaceuticals, WA, USA
stimulating factor (GM-CSF)
Hydrochloric acid (HCl) BDH Lab Supplies, Poole, England
IFN-  Boehringer Ingelheim Pty Ltd,
NSW, Australia
Interleukin-4 (IL-4) ProSpec, Ness-Ziona, Israel
Iodine (I) BDH Lab Supplies Ltd, Poole, England
Isopropanol BDH Lab Supplies, Poole, England
Lymphoprep Axis-Shield PoC AS, Oslo, Norway
L-Methionine Sigma Chemical Co., MO, USA
Methanol Merck, Darmstadt, Germany
Neopterin Schircks Laboratory, Switzerland
Oil Red O Sigma Chemical Co., MO, USA
Phenol Sigma Chemical Co., MO, USA
Phosphoric acid Sigma Chemical Co., MO, USA
Potassium bicarbonate (KHCO3) May & Baker Ltd, Dagenham, England
Potassium Iodide (KI) May & Baker Ltd, Dagenham, England
PrestoBlue Invitrogen, CA, USA
Sodium bicarbonate (NaHCO3) May & Baker Ltd, Dagenham, England
Sodium chloride (NaCl) BDH Lab Supplies Ltd,
Poole, England
Sodium dihydrogen orthophosphate Merck, Darmstadt, Germany
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(NaH2PO4)
Sodium dodecyl sulphate (SDS) Sigma Chemical Co., MO, USA
Sodium hydroxide (NaOH) Merck, Darmstadt, Germany
Sodium hypochlorite (NaOCl) Clorogene Supplies, Petone, New Zealand
Trypan blue solution (0.4%) Sigma Chemical Co., MO, USA
2.1.2 Media and Buffers
Penicillin/Streptomycin liquid; Invitrogen, CA, USA
1000 U of Penicillin G &
1000 µg of Streptomycin/mL
Roswell Park Memorial Institute (RPMI 1640);
- RPMI 1640 media, with phenol red Sigma-Aldrich Chemical Co., MO, USA
- RPMI 1640 media, without phenol red Sigma-Aldrich Chemical Co., MO, USA
Serum Free Media (SFM) for Macrophages Invitrogen, CA, USA
2.1.3 General Solutions, Buffers and Media
2.1.3.1 Blood Cell Lysis Buffer
Ammonium chloride (NH4Cl) (8.26 g) was dissolved in 1 L of nanopure
water along with 1 g of potassium bicarbonate (KHCO3) and 0.037 g of
ethylene-diamine-tetra-acetic acid (EDTA). The solution was stored at room
temperature.
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2.1.3.2 7,8-Dihydroneopterin Solution
7,8-Dihydroneopterin was prepared fresh prior to each experiment. A 2 mM stock
solution was prepared by sonicating 7,8-NP in ice cold RPMI 1640 until dissolved. The
stock solution was filter-sterilized via a 0.22 µmmembrane (Sartorius AG, Goettingen,
Germany). As 7,8NP is light sensitive the solution was always kept in the dark.
2.1.3.3 HPLC Mobile Phases
All aqueous solutions for HPLC were passed through a 0.45 µm filter and degassed via
sonication prior to use.
Ammonium phosphate ((NH4)2HPO4) buffer (20 mM) was prepared by dissolving
2.64 g of (NH4)2HPO4 in 900 mL of nanopure water. The pH was adjusted to 3.0 by
the addition of 10 M phosphoric acid. Nanopure water was added until the solution
reached a volume of 1 L, with a final concentration of 20 mM.
2.1.3.4 MTT assay solutions
The MTT stock solution was prepared by dissolving 5 mg/mL of
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) in phenol
red free RPMI 1640. This solution is light sensitive so after filter-sterilization (0.22
µmMS®PES syringe) it was kept the dark at  20  C.
Sodium dodecyl sulphate (SDS) (10% weight to volume ratio) was dissolved in
0.01 M hydrochloric acid (HCl). This solution was stored at room temperature.
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2.1.3.5 Oil Red O Stock Solutions
A 1 M concentrated citrate solution was prepared by dissolving 1.92 g of citric acid
in 10 mL of deionized water. Two millilitres of the concentrated solution was diluted
by the addition of 8 mL of deionized water and stored at 4  C. This diluted solution is
used to fix the cells prior to oil red O staining.
The oil red O stock solution was made by dissolving 300 mg of oil red O powder in
100 mL of isopropanol (99%). This solution was diluted for use at a ratio of 6 parts oil
red O stock solution to 4 parts distilled water. After 10 minutes standing, this diluted
solution was filtered through Whitman paper. The filtered working solution had a shelf
life of 1-2 hours.
2.1.3.6 Phosphate Buffered Saline (PBS)
Phosphate buffered saline (PBS) (150 mM sodium chloride (NaCl) and 10 mM sodium
dihydrogen orthophosphate (NaH2PO4), pH 7.4) for sterile use was autoclaved for 15
minutes at 121  C, 15 psi. This solution was stored at room temperature.
2.1.3.7 Roswell Park Memorial Institute 1640 Media
Following the manufacturer’s instructions, RPMI 1640 powder (with or without phenol
red) was dissolved in ultrapure water. Sodium bicarbonate (NaHCO3) was added and
the pH adjusted to 7.4 by the addition of concentrated HCl. The media was filtered
using a 0.22 µm Millex®-GP50 filter (Molsheim, SA) and a peristaltic pump (CP 600,
Life Technologies; New York, USA). The solution was stored at 4  C. RPMI 1640 for
cell culture work had 1000 U/mL penicillin-G and 1000 µg/mL streptomycin added
prior to use.
25
2. MATERIALS & METHODS
2.2 Methods
2.2.1 Blood Collection
The Canterbury Ethics Committee approved the use of human blood (98/07/069)
for these studies. Blood was collected from consenting patients during the
haemochromatosis clinic at the New Zealand Blood Bank (Riccarton Road,
Christchurch). Blood from patients was collected into either Compoflex® autologous
bags, containing the anticoagulant citrate-phophate-dextrose-adenine (CPDA-1)
for cell preparation, or dry bags (Fresenius Kabi; Homburg, Germany) for serum
preparation. Blood for cell preparation was either used within an hour of collection
or refrigerated overnight before use. Blood for serum preparation was cooled to room
temperature over 2 hours. The dry bag was placed at 4  C overnight to allow the blood
to clot and shrink.
The following procedures were performed under sterile conditions in a Class
II Laminar Flow hood (Clyde-Apex BH 200) to minimize bacterial and fungal
contamination.
2.2.2 Preparation of Human Serum
Dry blood bags were refrigerated overnight in a vertical position. Plasma was collected
from around the clotted blood and transferred to several 50 mL Falcon™ tubes
(Thermofisher Scientific; Indiana, USA). The tubes were centrifuged at 500 g for 15
minutes (Multifuge 1 S-R, Heraeus) to remove any remaining clotted material. The
serum was then transferred to new tubes for storage at  80  C.
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2.2.3 Isolation of Monocytes
RPMI 1640 was warmed to 37  C prior to addition. All other solutions and media used
in this procedure were warmed to room temperature before use.
The following procedure has previously been described by Yang (2009). Briefly,
blood from one autologous bag was transferred to 50mL Falcon™ tubes and
centrifuged for 30 minutes at 1000 g with slow deceleration. The buffy coat was
transferred into fresh 50 mL tubes (up to 15 mL per tube) and PBS was then added
to bring the total volume to 35 mL. Lymphoprep (15 mL), a Ficoll-Isopaque density
gradient medium which causes the aggregation and sedimentation of red blood cells,
was then carefully underlaid and the tubes were centrifuged for a further 30 minutes
as before. The monocyte layer, located approximately in the center of the tube, was
collected and transferred to new tubes (15 mL per 50 mL centrifuge tube). These
tubes were topped up to 50mL with PBS and centrifuged for 15 minutes at 500 g,
with the brake on to pellet the monocytes. The supernatant was discarded and the
pellet was resuspended in PBS to wash away the lymphoprep. The tubes were again
topped up to 50 mL and centrifuged for 10 minutes at 500 g, with the brake on. The
wash step was repeated twice more to remove any remaining lymphoprep. Finally, the
pellet was resuspended in serum-free RPMI 1640 (37  C) at a concentration of 5 x 106
cells/mL. The cells were transferred to 6 well suspension plates (Cellstar®, Greiner
Bio-one; North Carolina, USA) and placed into a humidified 5% CO2 incubator
(Sanyo MCO-5AC; Osaka, Japan) at 37  C.
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2.2.4 Cell Culture
2.2.4.1 Monocytes
After being isolated from whole blood, monocytes were incubated for 40 hours in 6
well plates to allow for T-cell death and the adherence of platelets. The monocytes
were gently removed from the 6 well plates, taking care not to disturb any adherent
particles. The collected cells were centrifuged for 10 minutes at 500 g. The monocytes
were then resuspended in fresh RPMI 1640 at a concentration of 10 x 106 cells/mL.
These cells were either pipetted into 12 well suspension plates (Cellstar®) at 500 µL
per well for experimentation, or diluted to 5 x 106 cells/mL with RPMI 1640 with 1%
human serum (HS) and stored in 6 well suspension plates for use within one week.
2.2.4.2 Macrophages
As described above in Section 2.2.4.1, isolated monocytes were removed from the 6
well plates, centrifuged and resuspended in RPMI 1640. Cells were resuspended at a
concentration of 5 x 106 cells/mL in RPMI 1640 with 10% HS. This solution was then
supplemented with 2 µL/mL of 25 µg/mL granulocyte macrophage colony stimulating
factor (GM-CSF). The cells were transferred into 12-well tissue culture plates (Nunc,
Nalge Nunc International; New York, USA) at a volume of 1000 µL per well. The
monocytes developed into macrophages over the course of two weeks. The media
(RPMI 1640 containing 10% HS) was changed every three to four days as determined
by the change in phenol red color. Phenol red is a pH indicator which turns yellow as
the media becomes acidic.
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2.2.4.3 Giant Cells
FBGCs are formed by the fusion of monocytes and macrophages in the presence of a
foreign body. Giant cells are distinctive with their many nuclei and large surface area.
Monocytes were isolated as described in Section 2.2.3. Immediately after isolation
the cells were seeded into 12 well tissue culture plates in RPMI 1640 with 10% HS.
After 40 hours, 800 µL of medium was removed from each well and replaced with the
same volume of fresh media. Five days from the initial seeding the RPMI 1640 was
replaced with serum free media (SFM) for macrophages. As determined by McNally
and Anderson (2003), the medium was supplemented with 50 µM ↵-TocH and 10
ng/mL IL-4. This media was changed every three to four days. The cells were ready
for experimentation eight days after seeding.
2.2.5 Oil Red O Staining
Oil red O is a polyazo dye that is lipid-soluble (McVean et al., 1965) and has been used
to stain adipose cells or areas of lipid deposits. Citrate working solution (see Section
2.1.3.5) was warmed to 37  C before use. Media was removed from the tissue culture
plate and the cells were washed twice with PBS. A fixative solution was prepared by
adding 3 parts acetone to 2 parts citrate working solution, and then 1 mL of fixative was
added to each well for 30 seconds. The cells were washed with distilled water before
the addition of 1 mL of oil red O staining solution. The stain was allowed to develop
for 10 minutes before being removed. One millilitre of 60% isopropanol/H2O (V /V )
was added to each well to remove any remaining stain that had not been incorporated
into the cells. The plate was washed thoroughly with distilled water, and then viewed
under a light microscope (DM IL, Leica; Wetzlar, Germany).
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2.2.6 Preparation of Cholesterol Crystals
Cholesterol crystals form in vivo in both bile and the necrotic core of plaques. To
reproduce this in vitro, a method of growing crystals using cholesterol powder was
adapted from Rajama¨ki et al. (2010). Powdered cholesterol (12.5g) was dissolved in
96% ethanol which had been heated to 65  C. This solution was left overnight to cool.
The ethanol was filtered through Whitman paper and the cholesterol crystals were left
for several hours to dry. The dry crystals were stored in a glass container at room
temperature until needed.
To prepare the crystals for addition to sterile cell culture, 100 mg of cholesterol
crystals was weighed out in a small paper holder and placed into a laminar flow hood.
The crystals were lightly covered in 100% ethanol to sterilize. The crystals were then
dried completely by waiting for the ethanol to evaporate before being added to 10
mL of RPMI 1640 (no phenol red) in a sterile glass container as the crystals adhere to
plastic. The solution was then placed in a sonicator for 20 minutes to break the crystals
into smaller fragments. This solution was refrigerated at 4  C until needed and warmed
to 37  C prior to use in any cell culture experiments.
2.2.7 Viability Assays
2.2.7.1 MTT Reduction Assay
The MTT reduction assay was carried out following the method adapted from
Mosmann (1983). Incubation media was removed from cell culture plate wells and
the cells were washed twice with PBS. RPMI 1640 (no phenol red) was mixed with 5
mg/mL MTT at a 9:1 ratio. To each well 1 mL of dilute MTT solution was added.
The tissue culture plates were returned to the incubator for 2 hours to allow the
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MTT to be reduced by cellular succinate dehydrogenase to form the purple formazan
crystals. Plates were removed from the incubator and 1 mL of warm 10% (W/V ) SDS
in 0.01 M HCl was added to each well to dissolve the formazan crystals. A blank
was prepared by adding all the reagents minus the cells. The blank was used to zero
the spectrophotometer (Shimadzu UV-1601PC UV-visible; Kyoto, Japan) and cuvettes
containing 1 mL of solution were read at 570 nm absorbance.
2.2.7.2 PrestoBlue™ Viability Assay
PrestoBlue™ (Invitrogen; New York, USA) is a resazurin-based, cell permeable
solution which turns red on contact with the reducing environment inside a viable cell.
For adherent cultures, treatment solutions were removed from the wells and the
cells were gently washed twice with PBS. PrestoBlue™ was diluted in RPMI 1640 (no
phenol red) at a 1:9 ratio and 400 µL of this dilute solution was added to each well.
Triplicate blanks containing only RPMI 1640 and PrestoBlue™ were also prepared.
Cells were incubated until control wells produced a pink color which occurred after
approximately 30 minutes. Two hundred microliters from each well was transferred
to a black Nunc Maxisorp 96-well plate. Fluorescence intensity was measured on a
POLARstar Galaxy microplate reader (BMG LABTECH; Ortenberg, Germany) using
an excitation wavelength of 544 nm and emission wavelength of 590 nm.
For non-adherent cultures, cells were collected from the wells and transferred
to 1.7mL microtubes (Axygen; California, USA). The tubes were centrifuged for 5
minutes at 500 g to pellet the cells. The supernatant was removed via aspiration. After
this, 200 µL of warm RPMI 1640/PrestoBlue™ (9:1) was added to each microtube.
Cells were incubated with the solution as described above and then transferred into a
96-well plate. Fluorescence intensity was measured as described above.
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2.2.7.3 Trypan Blue Exclusion Assay
The trypan blue exclusion assay was adapted from the method of Moldeus et al. (1978).
For non-adherent cells, the solution in each well was gently pipetted up and down to
mix before 50 µL was transferred to a microtube. Next, 50 µL of trypan blue stain
(0.4%) was added to the tube and gently mixed with the cell solution. Tubes were left
for 2 minutes to allow the dye to permeate any non-viable cells. A haemocytometer
(Marienfeld, Germany) was used to count the proportion of dead (blue-stained) cells
compared to viable (non-stained cells). For adherent cells, the incubation media was
first aspirated and then 50 µL of trypan blue stain (0.4%) was added directly to the cell
culture plate. After 2 minutes the Trypan blue was aspirated from the wells. The cells
were washed twice with PBS to remove any remaining stain that had not been taken
up. The adherent cells were viewed under an inverted light microscope. Dead and live
cells were counted in 5 fields of view for each well.
2.2.8 HPLC Pterin Analysis
2.2.8.1 Cell Preparation
Non-adherent cells were pipetted into microtubes and centrifuged at 500 g for 5
minutes to pellet the cells. To prepare the extracellular samples, 200 µL of supernatant
from each tube was transferred into two microtubes (100 µL into each). These samples
were then processed following the methods described in Sections 2.2.8.2 and 2.2.8.3.
To prepare the intracellular samples, the rest of the supernatant from the original
microtube was aspirated off. The remaining cell pellet was washed twice with PBS.
Finally, the pellet was resuspended in 200 µL of PBS, ready to be processed for
neopterin analysis (see Section 2.2.8.2). Half of this sample was transferred to another
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microtube for total pterin analysis (see Section 2.2.8.3).
For adherent cells, extracellular supernatant samples were collected directly from
the cell culture plates. From each well, 200 µL of supernatant was transferred into
two microtubes (100 µL into each). One tube was prepared for neopterin analysis,
the other for total pterin analysis. For the intracellular samples, first all the remaining
supernatant was aspirated off and then 200 µL of PBS was added to each well. Using
the tip of the pipette as a scraper, adherent cells were lifted off the plate and transferred
into microtubes. The cells were gently pipetted up and down to resuspend in the PBS.
The solution was transferred into two microtubes (100 µL into each) for neopterin and
total pterin analysis.
2.2.8.2 Neopterin Sample Preparation
All tubes had 100 µL of 100% acetonitrile (ACN) added to induce protein precipitation.
ACN is ideal as it is able to precipitate protein without causing the loss of 7,8-NP
which can occur with acidic protein precipitation (Flavall et al., 2008). The tubes
were vortexed before being centrifuged for 10 minutes (20,300 g, 4  C) to pellet the
precipitated material. Fifty microliters from each tube was transferred into HPLC vials
ready for injection.
2.2.8.3 Total Pterin Sample Preparation
As described in Section 2.2.8.2, 100 µL of ACN was added to each tube to induce
protein precipitation. This material was then pelleted by centrifugation. After this,
40 µL of acidic iodide (5.4% (W /V ) iodine and 10.8% (W /V ) potassium iodide in 1 M
HCl) was added. Acidic iodide converts any 7,8-NP into neopterin by oxidation. The
tubes were briefly vortexed and then incubated in the dark for 15 minutes. After the
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incubation, 20 µL of 0.6 M ascorbic acid was added to reduce any remaining iodide
and the tubes were briefly vortexed again. Finally, the tubes were centrifuged for 10
minutes (20,300 g, 4  C) to ensure the sample was precipitate free prior to injection.
Fifty microliters was pipetted into a HPLC vial.
2.2.8.4 Sample Analysis
The pterin analysis was carried out using a Phenomenex Luna® 5 µm SCX, 50 x
4.6 mm column (California, USA) heated to 35  C. The column separates positively
charged compounds by ion exchange.
A 20 mM ammonium phosphate (pH 3) mobile phase was prepared (see Section
2.1.3.3). A 90% ammonium phosphate/ACN mixture was pumped through the column
at 1 mL/minute, with 10 µL of each sample being injected onto the column. Neopterin
was measured by a fluorescence detector (RF-20Axl, Shimadzu Corporation; Japan)
using an excitation of 355 nm and emission of 438 nm. Neopterin typically had a
retention time of 4.2 minutes which was confirmed using a neopterin standard. The
concentration of neopterin in samples were calculated from the peak size of known
standards (50 nM and 25 nM) of neopterin. The concentration of 7,8-NP can be
calculated by finding the amount of total pterin in a sample and subtracting the value
obtained for neopterin.
2.2.9 ELISA
The IL-1  enzyme-linked immunosorbent assay (ELISA) kit (Invitrogen; New York,
USA) was performed according to the manufacturer’s instructions. This sandwich
assay relies on the target molecule binding to the primary antibody which is present on
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the ELISA plate. The addition of the secondary antibody forms the “sandwich” around
the target molecule. The presence of the target molecule is quantified by the addition
of a luminescent reagent.
A standard curve of IL-1  was prepared by serial dilution from the standard
provided. One hundred microliters of each diluted standard was pipetted in the 96-well
plate provided. The same volume of non-diluted supernatant from samples was also
pipetted into the plate. The standards and samples were then incubated for two hours
at room temperature. After this incubation period, the wells were aspirated and the
plate was thoroughly washed. Next, the secondary antibody (100 µL) was added
to each well and the plate was incubated for one hour. Again, after the incubation
period the solution was aspirated and the plate was washed. Finally, 100 µL of the
chemiluminescent reagent was added. The plate was read after 30 minutes incubation
in the dark. The luminescence was measured on SpectraMax M5 microplate reader
(Molecular Devices; California, USA) using a 1000 msec integration time and a
five-parameter algorithm to fit the standard curve.
2.2.10 Statistical Analysis
Prism 6.0 (GraphPad Software; California, USA) was used to graph and statistically
analyze data. Significance is indicated as follows: p0.05 - *, p0.01 - **, p0.001 -
***, p0.0001. Results in this thesis are presenting data from a single experiment that
is representative of three separate experiments unless stated otherwise. All experiments
were performed in triplicate (unless otherwise stated). The mean and standard error of
the mean (SEM) were calculated from the triplicate data.
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3Culture of Foreign Body Giant Cells
The aim of this chapter is to explore the potential of giant cells as an in vitro model
of the foreign body response occurring in atherosclerotic plaques due to cholesterol
crystals. The experiments in this chapter will analyze whether or not giant cells can be
successfully cultured and used as an experimental system. Human monocyte-derived
macrophages (HMDMs) are an example of a well documented, established culture
system (the history of the discovery and use of macrophages is reviewed in Gordon
(2007)). As HMDMs are the progenitor of the giant cell lineage they will act
as a comparison throughout this chapter against which giant cell culture can be
standardized.
3.1 Introduction
By the late 19th century it was already known that giant cells form by the fusion of
individual monocyte or macrophage cells around foreign-bodies as opposed to cell
division (Metchnikoff, 1884). There is a strong histological record documenting the
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occurrence of giant cells in inflammatory conditions. Unfortunately, whilst in vivo and
ex vivo procedures are well documented, very few in vitro methods of culturing giant
cells exist. Deriving giant cells from a cell line would produce a highly replicable
system. However, previous research has found that monocyte-like cell lines U937 and
THP-1 are unable to form giant cells even after 15 days of stimulation with cytokines
(Jay et al., 2010). Hence, monocytes isolated from human blood are used in this
research.
To complicate matters a number of different factors, commonly referred to as
fusion molecules, have been shown to induce fusion. These include but are not limited
to: RANKL, M-CSF, interleukin-3 (IL-3), and IFN-  (Helming and Gordon (2009)
provide an extensive review of fusion molecules). Different fusion factors result in
varying phenotypes of giant cells (refer to Section 2.2.4.3). It is important for this
work that the phenotype induced is the foreign-body giant cell as the aim is to model
the foreign-body response to cholesterol crystals. IIL-4 and ↵-TocH were selected as
fusion molecules for the experiments in this chapter as they have been shown to induce
this phenotype (McNally and Anderson, 2003).
Previous studies have used sub-optimal concentrations for the specific purpose
of inducing further fusion with other fusogenic molecules (McNally and Anderson,
1995). In this chapter optimal concentrations of both IL-4 and ↵-TocH are sought
by experimental testing. For the purposes of this thesis, the optimal concentration is
determined by the highest number of giant cells formed above the baseline using the
smallest quantity of the fusion mediators. This is in part to maintain an economically
feasible cell culture system.
Having established an optimal concentration of fusogenic factors, it is important to
select a method for obtaining cell viability. No studies of giant cell viability have been
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published so two methods measuring different aspects of cell viability were chosen
to be tested. MTT reduction and trypan blue exclusion assays are commonly used
to assess cell viability. The MTT reduction assay uses the metabolic activity of the
cells to determine viability, whereas trypan blue exclusion relies on the fact that intact,
healthy cells will exclude the dye but dead or compromised cells will be permeable and
stain brightly blue. This chapter will explore the validity of these methods in respect
to the measurement of giant cell viability.
Finally, it has been hypothesized that giant cells are capable ingesting cholesterol
crystals by endocytosis in vivo. However, this has not been tested in vitro. This
chapter will examine the ability of giant cells to absorb cholesterol crystals compared
to HMDM cells. It will also examine the effect of the cholesterol crystals on cell
viability using the methods established earlier.
3.2 Results
3.2.1 Identifying Giant Cells
In order for giant cells to be a viable option for cell culture experimentation, they
need to be easily distinguished from normal HMDMs. It has been suggested that
giant cells can be identified by their cytoplasmic spreading and lamellipodia formation
(MacLauchlan et al., 2009).
To test this, human monocytes were cultured for an initial 4 days in RPMI 1640
with 10% HS (as described in Section 2.2.4.3). On the fifth day the cells were
transferred into SFM and 10 ng/mL of IL-4 and 50 µM ↵-TocH were added. The
cells were then cultured for a further 6 days. The cells were were stained with oil red
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O (see Section 2.2.5), as it has been shown previously that giant cells contain large
lipid droplets (Kosteli et al., 2010). They were then photographed using an inverted
light microscope. Figure 3.1a shows that staining giant cells with oil red O makes
them clearly visible. Giant cells stain heavily for lipid deposits whereas neighboring
macrophages do not. This technique allows the giant cells to be quantified. However, a
major draw back of this technique is that the cells must be fixed before staining which
prevents any further experiments being carried out on the cells.
In fact, most techniques that would allow giant cells to be easily visible in cell
culture require the cells to be fixed or cause permanent changes to the cell. It was
investigated whether giant cells could be distinguished and quantified without the aid
of any dyes, stains, or tags. Fortunately, giant cells possess a distinct morphology from
HMDMs. Unstained cells can be identified as shown in Figure 3.1b by their distinctive
shape, granularity and size. The average size of the giant cell after 10 days in culture
is 79.97 µm ± 4.973 (N=6) compared to 23.5 µm ± 1.024 (N=6) for HMDM cells
(see Figure 3.2). As giant cells are significantly larger than macrophages, they can be
differentiated from HMDMs based on their size.
As further cytoplasmic spreading takes place giant cells become more difficult
to identify (Figure 3.3a). After two weeks in culture many cells have lost their
macrophage-like morphology and have become exceptionally thin. This thinness
makes the cells difficult to identify using bright phase or IMC microscopy as the edges
of the cell blend in with the background of the image. Often a giant cell can be most
easily identified by an apparent gap surrounded by monocytes. Another microscopy
technique, dark phase microscopy, improves the ability to distinguish giant cells from
one another but gives poor image clarity (see Figure 3.3b). Dark phase microscopy
allows the visualization of unstained transparent cells by causing a phase shift which
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(a) Oil red O stained giant cell
(b) Unstained giant cell
Figure 3.1: Foreign body giant cells in culture. (a) The giant cell stained with oil red
O is showing lamellipodia formation (indicated by arrowheads) Image was taken at 20x
magnification. (b) The unstained giant cell, as indicated by the arrowhead, is showing
cytoplasmic spreading. Image was taken on an inverted microscope at 40x magnification
using IMC. Scale bars represent 50 µm.
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Figure 3.2: Comparison of HMDM and giant cell (GC) size - Cells were cultured
for 10 days before having their size measured. The size was calculated using ImageJ
software to analyze the diameter of each cell. An average of cell size in two fields of view
was calculated per well. Data are from a single experiment that is representative of three
independent experiments. Data shown is ± SEM of triplicate measurements. Significance
is indicated as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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results in differences in brightness between the background and the object that is being
identified. Dark phase microscopy is only appropriate when there is a single layer of
cells, which is not always the case in HMDM and giant cell culture.
It seems giant cells can be identified with ease during their early stages of
development prior to any significant cytoplasmic spreading. The identification of giant
cells after more than two weeks is more complex and most likely would require some
type of staining such as with oil red O.
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(a) Light microscopy
(b) Dark phase microscopy
Figure 3.3: Cytoplasmic spreading of foreign body giant cells. (a) The boundaries
(indicated by the arrowhead) of foreign body giant cells are difficult to distinguish even
at high magnification. (b) Dark phase microscopy highlights the area and boundaries of
giant cells. Images were taken on an inverted microscope at 40x magnification. The scale
bar on each image represents 50 µm.
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3.2.2 Optimal Interleukin-4 and ↵-Tocopherol Concentrations to
Induce Giant Cell Fusion
Macrophage fusion is difficult to quantify and highly variable from culture to culture.
In order to find the optimum concentrations of IL-4 and ↵-TocH, cells were treated
with either IL-4 or ↵-TocH at a range of concentrations for 7 days. After this time
the effect of treatment was examined by microscopy (see Figure 3.4). The degree of
fusion was determined by calculating the percentage of giant cells present compared
to the total number of cells in the particular field of view. As the average size of an
HMDM was determined earlier as being 23.5 µm, any cell over 40 µm was designated
as a giant cell.
Untreated HMDMs cultured in SFM without the addition of ↵-TocH or IL-4
showed a baseline fusion of 3.5% (Table 3.1). The addition of 10 ng/mL IL-4 resulted
in a 1.5 fold increase in fusion over untreated cells. Cells given 15 ng/mL showed a 1.8
fold increase, and those given 20 ng/mL showed a 2 fold increase. Whilst IL-4 alone
is capable of inducing a low level of fusion, the rates seen here are not ideal. These
results are counter to the available literature which suggests these concentrations of
IL-4 should induce much higher rates of fusion.
It has also been proposed that ↵-TocH can induce giant cell formation by causing
PS flipping (Helming et al., 2009; Klein et al., 2006). Cells treated with 25 µM ↵-TocH
showed a 1.9 fold increase in fusion over the control. Treatment with 50 µM and 75
µM resulted in a 3.8 and 4.1 fold increase respectively. Neither IL-4 nor ↵-TocH alone
induced significant amounts of fusion so cells were treated with a combination of both
(see Figure 3.5). The results of the previous experiment had shown no significant
difference between IL-4 concentrations so the experiment was repeated with both 10
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Figure 3.4: Effect of ↵-tocopherol and IL-4 on giant cell culture - On day 5 of cell
culture, ↵-TocH or IL-4 was added to fresh cell culture media in increasing concentrations.
All cells were stained with oil red O to aid in the identification of giant cells. Images are
representative of triplicate wells per experimental treatment. The images were taken on an
inverted light microscope at 20x magnification.
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Figure 3.5: Effect of IL-4 on giant cell fusion - All cells were seeded at a concentration
of 5 x 106 cells/mL and cultured in SFM for 7 days after the addition of the treatment.
Control cells were treated with 50 µM ↵-TocH only. The images were taken on an inverted
light microscope at 20x magnification.
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and 15 ng/mL of IL-4.
As increasing the concentration of ↵-TocH from 50 µM to 75 µM showed very little
improvement in macrophage fusion the experiment was performed in the presence of
50 µM ↵-TocH. Increasing the concentration of IL-4 from 10 ng/mL to 15 ng/mL
boosted cell fusion by 8.3%. The addition of 50 µM ↵-TocH and 15 ng/mL IL-4
improved fusion by 25.6% over the cell only control. All experiments from this point
onwards were carried out using the optimal concentrations of 15 ng/mL IL-4 and 50
µM ↵-TocH.
Table 3.1: Maximum percentage of giant cell formation after treatment with ↵-tocopherol
and interleukin-4.
Concentration 0 µM ↵-TocH 25 µM 50 µM 75 µM
0 ng/mL IL-4 3.5% 6.7% 13.3% 14.2%
10 ng/mL 5.4% - 20.8% -
15 ng/mL 6.2% - 29.1% -
20 ng/mL 7.1% - - -
3.2.3 Measurement of Giant Cell Viability
A thorough literature search has failed to yield any evidence of giant cells being tested
for viability. Either this has never been attempted or has never been published. To
study the viability of giant cells two common measures of cell viability were used.
MTT reduction is a metabolism based assay whereas trypan blue is an exclusion based
assay using membrane integrity as its measure. The viability assays were performed
on healthy HMDMs and giant cells after two weeks in cell culture.
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Figure 3.6: Viability of HMDMs and GCs as measured by MTT reduction assay -
HMDMs and GCs seeded at 5 x 106 cells/mL were incubated for 12 days in RPMI 1640
and SFM respectively. The cells were incubated with MTT for 2 hours prior to absorbance
being read. The data in the graph is from four independent experiments performed in
triplicate. Data shown is the mean of the means ± SEM. Significance is indicated as
follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
49
3. CULTURE OF FOREIGN BODY GIANT CELLS
The cells were incubated with MTT for 2 hours before the cell viability was
analyzed by spectroscopy. Figure 3.6 shows that giant cells have an average
absorbance of 0.56 ± 0.08 AU (N=12) compared to 0.94 ± 0.12 AU (N=12) for
HMDM cells. Untreated cells are expected to fall between 0.75 and 1.25 AU, so
that absorbance measurements are made in the linear part of the curve. Seeding 5
x 106 cells produced the correct amount of formazan in the HMDM cells but not in the
giant cells. This suggests that either fewer cells are present in the giant cell cultures
or the giant cells are less capable of metabolizing MTT than HMDMs. If the lack of
formazan production was due to a lower number of cells present, then allowing the
culture to incubated for longer with the MTT reagent should increase the production
of formazan.
To test the ability of giant cells to metabolize MTT, cells were incubated for 2
hours and 24 hours and then photographed. Figure 3.7a shows very little production
of formazan crystals after 2 hours in the giant cell culture compared to control HMDM
cells (Figure 3.7b). Even after 24 hours the giant cells still failed to produce formazan
crystals (Figure 3.7c).
In comparison, cells stained with trypan blue showed close to 98% viability
(Figure 3.8). There was very little difference between replicates of HMDM cells.
There was some variation between replicates of giant cells but the range was much
smaller than seen with MTT. Using the trypan blue, there was no significant difference
in the average cells per field of view between HMDMs and giant cells (Figure 3.9).
These results suggest that MTT is not an appropriate tool for measuring giant
cell viability, but trypan blue appears to give a fairly accurate measure of viability.
Experiments from this point on involving giant cells and cell viability will use trypan
blue.
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(a) GCs after 2 hour incubation with MTT
(b) HMDMs after 2 hour incubation with MTT
(c) GCs after 24 hour incubation with MTT
Figure 3.7: Giant cells are unable to produce significant quantities of formazan
crystals. HMDMs and GCs seeded at 5 x 106 cells/mL were incubated for 12 days in
RPMI 1640 and SFM respectively. The cells were incubated with MTT for either 2 or 24
hours. Images were taken on a light microscope. Scale bars represent 100 µm.
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(a) Viability of GCs and HMDMs measured by trypan blue
exclusion assay
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Figure 3.8: Cell viability as measured by trypan blue exclusion assay. HMDMs and
GCs seeded at 5 x 106 cells/mL were incubated for 12 days in RPMI 1640 and SFM
respectively. HMDM and GCs had trypan blue added before being counted on an inverted
light microscope with a magnification of 20x. Data are of 5 random images per well.
Each treatment was performed in triplicate. Data is from a single experiment that is
representative of 3 independent experiments. Data shown is the mean ± SEM of triplicate
measurements. Significance is indicated as follows: p0.05 - *, p0.01 - **, p0.001 -
***, p0.0001.
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Figure 3.9: Comparison of cell count between HMDMs and GCs - HMDMs and
GCs seeded at 5 x 106 cells/mL were incubated for 12 days in RPMI 1640 and SFM
respectively. HMDM and GCs had trypan blue added before being counted on an inverted
light microscope with a magnification of 20x. Data are representative of 5 random images
per well. Each treatment was performed in triplicate. Data is from a single experiment
that is representative of 3 independent experiments. Data shown is the mean ± SEM of
triplicate measurements. Significance is indicated as follows: p0.05 - *, p0.01 - **,
p0.001 - ***, p0.0001.
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3.2.4 Formation of Cholesterol Crystals
Foreign body giant cells are thought to form around cholesterol crystals in order to
absorb them (Bayliss, 1976; Samokhin et al., 2010). In vivo, cholesterol crystals
naturally form in areas of extracellular lipid deposits (Bocan et al., 1986). However,
nucleation of cholesterol crystals has also been achieved in vitro using lipid-laden
macrophage foam cells (Tangirala et al., 1994). For experiments in this chapter,
cholesterol crystals were produced through the addition of cholesterol to hot ethanol
and allowing the mixture to cool (see section 2.2.6). Initially the crystals were too
large to transfer via a 1000 µL pipette, so the mixture was sonicated to break the
crystals into a more manageable size. This had the additional benefit of making the
crystals a comparable size to the macrophages.
Figure 3.10: Cholesterol crystals - Cholesterol crystals have been sonicated to produce
smaller fragments no larger than 50 µm in diameter.
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3.2.5 Absorption of Cholesterol Crystals by Cells
It is thought that giant cells are able to actively absorb cholesterol crystals as a means
of removing a foreign body. Cholesterol crystals in vivo can grow up to 200 µm in size
(Moolenaar and Lamers, 1996). Crystals of less than 10 µm can be easily phagocytized
by macrophages as they are much smaller than the macrophage itself. To model
inefficient cholesterol reabsorption, the majority of crystals had a diameter above 20
µm but no larger than 50 µm. It was not possible to create a uniform cholesterol
crystal size with the techniques available, however this diversity in size reflects the in
vivo development of crystals.
Both HMDMs and giant cells were incubated with 5.0 mg/mL of cholesterol
crystals for 7 days to test their ability to absorb the crystals (see Figure 3.11). This
concentration of cholesterol crystals was chosen as it completely covered the well.
HMDMs after 7 days showed some clearance of the cholesterol crystals as can be seen
in Figure 3.11a. The amount of clearance occurring is difficult to quantify, but using
Image J software to highlight the remaining crystals, it was estimated to be around
50%. The same technique applied to giant cells shows cholesterol crystal clearance of
approximately 21%. It appears that giant cells cannot metabolize as many cholesterol
crystals as HMDMs. This result is in agreement with microscopy and histological data
(Friedmann and Graham, 1979). Both giant cells and HMDMs were incubated with
cholesterol crystals for a further 7 days to test whether any further crystal absorption
occurred (data not shown). It was found that no further absorption occurred.
Incubating cells with cholesterol crystals had little effect on their viability
according to measurements made using trypan blue exclusion staining (see Figure
3.12a). The viability of giant cells compared to HMDMs was significantly different,
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(a) HMDM with cholesterol crystals
(b) Giant cells with cholesterol crystals
Figure 3.11: Absorption of cholesterol crystals HMDM and GCs - A) HMDMs
showing significant absorption of cholesterol crystals after 7 days. B) GCs showing
little absorption of cholesterol crystals after 7 days. Images were taken on an inverted
microscope at 10x magnification. Scale bar represents 100 µM.
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with giant cells having a mean viability of 90.81% ± 1.977 (N=15) compared to
98.46% ± 0.4065 (N=14) for HMDMs. Whilst the difference between HMDMs and
giant cells is statistically significant, in terms of a biological system this is a very small
percentage cell death.
Viability obtained using trypan blue exclusion staining is calculated by measuring
the proportion of live cells in five fields of view in three separate wells for each
treatment. It would be expected that each well, or replicate, would produce a
similar result to the other two replicates. As expected, HMDM replicates showed
very little variation from one another. Giant cell replicates showed much higher
intraexperimental variation (see Figure 3.12b). Replicate 3 differed significantly
from both replicate 1 and 2. Replicate 3 had a mean of 84.04% ± 4.413 (N=5)
compared to means of 92.42% ± 1.328 and 95.98% ± 1.001 (N=5) for replicate 1
and 2, respectively. Observing the giant cell culture revealed that the coverage and
number of cells present was much less uniform than the HMDM culture. It is also
possible that the presence of cholesterol crystals are introducing some of the variability
as Figure 3.8b, where trypan blue staining was completed in the absence of cholesterol
crystals, showed less variability. These factors appear to be influencing the results of
the viability assay.
From these results it appears that cholesterol crystals are largely non-toxic to cells
in vitro. It also appears that the ability of cells to absorb cholesterol crystals is reduced
when macrophages are transformed into giant cells.
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(a) Effect of cholesterol crystals on viability of HMDM and GCs
measured by Trypan blue exclusion assay
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Figure 3.12: Cells remain viable after treatment with cholesterol crystals. HMDMs
and GCs seeded at 5 x 106 cells/mL were incubated for 12 days in RPMI 1640 and SFM
respectively. Cholesterol crystals (1.0 mg/mL in serum free RPMI 1640) were added to
the culture on day 13 and the cells were incubated for a further 24 hours. Cell viability
was measured by direct addition of trypan blue to the wells. Data are representative of 5
random images per well. Each treatment was performed in triplicate. Data is from a single
experiment that is representative of 3 independent experiments. Data shown is the mean
± SEM. Significance is indicated as follows: p0.05 - *, p0.01 - **, p0.001 - ***,
p0.0001.
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4Pterin Production in Monocytes and
HMDMs in Response to Cholesterol
Crystals
The aim of this chapter is to investigate the effect of cholesterol crystals on neopterin
and total pterin production in monocyte and monocyte-derived cells. The experiments
in this chapter will explore the effect of cholesterol crystals in the presence and absence
of IFN- . It will also investigate the production of IL-1  in monocytes and whether
pterins have an impact on this production.
4.1 Introduction
There remains some debate as to whether cholesterol crystals are an inflammatory
stimulus. Recent research has shown that cholesterol crystals activate the NLP3
inflammasome in a concentration-dependent manner (Duewell et al., 2010). This
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chapter will explore the inflammatory nature of cholesterol crystals using a common
measure of inflammation, that is, neopterin. Currently, no studies have investigated
whether cholesterol crystals are able to induce the production of 7,8-NP and neopterin
in monocyte-derived cells. By using IFN- , which is known to stimulate pterin
production, as a positive control, the ability of cholesterol crystals to modulate the
production of pterins can be studied. In Chapter 3 it was shown that HMDMs and
giant cells had different capabilities regarding the absorption of cholesterol crystals.
Absorption of the cholesterol crystal appears to be a key element in activating
inflammation. As this ability differs between cell phenotypes, it is has yet to be
established whether cholesterol crystals can cause different inflammatory responses
in different cell types. This chapter will examine the effect of cholesterol crystals on
monocytes, HMDMs and mixed culture. Finally, it is known that cholesterol crystals
induce IL-1  production through activation of the inflammasome. However, it is not
known whether the presence of 7,8-NP has an effect on this production.
4.2 Results
4.2.1 Effect of Cholesterol Crystal Concentration on Pterin
Production in HMDMs
HMDMs (1 x 106 cells/mL) were incubated with cholesterol crystals for 24 hours
to investigate whether there was an effect of cholesterol crystal concentration on the
production of intracellular and extracellular pterins. Neopterin is highly fluorescent
which means it can be directly measured by HPLC. 7,8-NP, however, does not have
the same fluorescent property. The level of 7,8-NP is measured indirectly by oxidizing
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the 7,8-NP in the sample to neopterin. After oxidation, the sample contains both the
original neopterin as well as the neopterin oxidized from 7,8-NP so it is termed total
pterin. The concentration of 7,8-NP in the sample can then be inferred by calculating
the difference between neopterin and total pterin.
Cholesterol crystals were observed to have little effect on neopterin production in
HMDMs (Figure 4.1a). Only 10 mg/mL of cholesterol crystals induced a small rise
in intracellular neopterin (0.65 ± 0.099 pmol per 1 x 106 cells compared to 0.60 ±
0.037 in the control), however, this rise was not statistically or biologically significant.
Cholesterol crystals did cause a statistically significant reduction in total pterin at 0.5,
5 and 10 mg/mL. This reduction was not seen at 1 mg/mL of cholesterol crystals.
The presence of cholesterol crystals resulted in less intracellular 7,8-NP production
compared to the cell only control (Figure 4.1b). It appears that the reduction in
intracellular 7,8-NP is significantly correlated with cholesterol crystal concentration
(R2=0.82, p=0.034). This dose-dependent reduction in 7,8-NP occurs with
concentrations up to 1 mg/mL of cholesterol crystals in the extracellular fraction (see
Figure 4.2). At concentrations above 5 mg/mL the amount of 7,8-NP produced appears
to plateau. Due to this semi-biphasic response, the cholesterol crystal concentration
does not explain the variation in extracellular 7,8-NP levels with R2=0.001, p=0.956. It
was suggested that cholesterol crystals may have a direct interaction with extracellular
neopterin or 7,8-NP. Cholesterol crystals were incubated with neopterin and 7,8-NP
in a cell free environment in order to establish whether cholesterol crystals could
modify pterin levels by direct interaction in the absence of cells. It was confirmed
that cholesterol crystals had no impact on neopterin or 7,8-NP concentrations in a cell
free environment (data not shown).
From the results indicated in Figures 4.1 & 4.2, 5 mg/mL of cholesterol crystals
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was selected for use in all further experiments. Incubating cells with 5 mg/mL
produced minimal intraexperimental variation and had a consistent effect on both the
intracellular and extracellular production of pterins. Other experiments found that this
concentration also gave the least variability in terms of cell viability (data not shown).
The levels of pterins produced in these experiments were at the limits of detection for
the HPLC, so future experiments were carried out with a higher concentration of cells
(5 x 106 cells/mL) which produces a stronger signal on the HPLC chromatograph.
It was interesting that there was less neopterin and total pterin produced by cells
incubated with cholesterol crystals. The cholesterol crystals appear to be having a
inhibitory effect on pterin levels. To further investigate this, cells were incubated with
both cholesterol crystals and IFN- , to stimulate GTPCH-1, the enzyme that converts
GTP to the precursor of 7,8-NP and neopterin (Section 4.2.2).
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(a) Intracellular neopterin and total pterin production after 24 hours
in HMDMs
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(b) Intracellular 7,8-NP production after 24 hours in HMDMs
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Figure 4.1: Effect of cholesterol crystal concentration on intracellular pterin
production in HMDMs. HMDMs (1 x 106 cells/mL) were incubated for 24 hours with
increasing concentrations of cholesterol crystals. Neopterin and total pterin were measured
by HPLC analysis. The graphs are of data from a single experiment that is representative
of three separate experiments. Data are mean values ± SEM of triplicate measurements.
Statistical significance is calculated compared to control values. Significance is indicated
as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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(a) Extracellular neopterin and total pterin production after 24 hours
in HMDMs
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(b) Extracellular 7,8-NP production after 24 hours in HMDMs
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Figure 4.2: Effect of cholesterol crystal concentration on extracellular pterin
production in HMDMs. HMDMs (1 x 106 cells/mL) were incubated for 24 hours with
increasing concentrations of cholesterol crystals. Neopterin and total pterin was measured
by HPLC analysis. The graphs are of data from a single experiment that is representative
of three separate experiments. Data are mean values ± SEM of triplicate measurements.
Statistical significance is calculated compared to control values. Significance is indicated
as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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4.2.2 Pterin Production After 24 hours of Incubation with
Cholesterol Crystals
It is hypothesized that cholesterol crystals may be able to induce pterin production in
macrophages, as it is thought that cholesterol crystal are an inflammatory stimulus, and
that macrophages are involved in the clearance of these crystals. Compared to other
processes occurring in the body, pterin production is rather slow as it is modulated at
the gene expression level (Katusic et al., 1998). It was decided that pterin production
would be analyzed after 24 hours as studies by Huber (1984) have shown that HMDMs
begin to produce 7,8-NP and neopterin after this time.
4.2.2.1 HMDMs
From previous experiments (Figure 3.12), it was already known that cholesterol
crystals are non-toxic to cells. To investigate the potential toxicity of IFN-  a cell
viability assay was used which quantified the proportion of live cells prior to sample
preparation for HPLC. This was carried out to make sure cell death due to any of
the treatments was not confounding the results. Prestoblue, a resazurin-based cell
permeable solution, was chosen as the reagent for the cell viability assay for all pterin
experiments as it has several advantages over MTT and trypan blue. Not only is
prestoblue a much faster assay procedure than MTT, but also the assay leaves cells
viable for further experimentation, unlike both MTT and trypan blue. The prestoblue
does not interfere with the HPLC as it fluoresces at an excitation of 544 nm and
emission of 590 nm whereas neopterin is excited at 353 nm and emits at 438 nm
(Demel et al., 2001). HMDMs were incubated with the treatments for 24 hours,
after which remaining cell viability was measured. Cell viability is presented as
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a percentage viability remaining compared to control HMDMs in RPMI 1640 only
which are adjusted to 100%. Figure 4.3 reveals that there is no viability loss associated
with any of the treatments. Cells treated with cholesterol crystals (CHC), either alone
or in the presence of IFN- , show a slight increase in viability compared to the control.
The viability of HMDMs treated with both IFN-  and cholesterol crystals is 124.6%
± 3.4, approximately 25% higher than the control. HMDMs treated with cholesterol
crystals alone have 110.0% ± 10.7 viability, but this 10% increase was not significant.
Table 4.1: Experimental set up for HMDM pterin measurement
Control IFN-  IFN-  + CHC CHC
10,000 U/mL IFN-  0 µL 10 µL 10 µL 0 µL
10 mg/mL CHC 0 µL 0 µL 500 µL 500 µL
RPMI 1640 1000 µL 990 µL 490 µL 500 µL
Total 1000 µL 1000 µL 1000 µL 1000 µL
Having established that all of the treatments were non-toxic to HMDMs, pterin
production was measured. All pterin experiments with HMDMs in this chapter follow
the experimental set up detailed in Table 4.1. In these experiments, HMDM cells,
incubated in RPMI 1640 only, are the negative control. HMDMs stimulated with
IFN-  only act as the positive control. IFN-  is known to induce 7,8-NP production in
a dose-dependent manner by upregulating GTPCH-1 mRNA, the enzyme that converts
GTP to 7,8-NP-PPP as discussed in Section 1.8. It has previously been shown that
100 U/mL of IFN-  is sufficient to induce 7,8-NP production in monocyte-derived
cells (Wirleitner et al., 2002). Interestingly, HMDMs incubated with 100 U/mL IFN- 
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Figure 4.3: HMDM cell viability after 24 hours - HMDMs (5 x 106 cells/mL) were
incubated at 37  C in RPMI 1640 with 5 mg/mL of cholesterol crystals and 100 U/mL
IFN-  for 24 hours. Controls were conducted in the absence of cholesterol crystals and
IFN- . HMDMs were analyzed for remaining cell viability using PrestoBlue. The graphs
are of data from a single experiment that is representative of three separate experiments.
Data are mean values ± SEM of triplicate measurements. Statistical significance is
calculated compared to control values. Significance is indicated as follows: p0.05 -
*, p0.01 - **, p0.001 - ***, p0.0001.
67
4. PTERIN PRODUCTION IN MONOCYTES AND HMDMS IN RESPONSE
TO CHOLESTEROL CRYSTALS
failed to show any significant neopterin or 7,8-NP production above the levels shown
by the control either intracellularly or extracellularly (Figure 4.4). The intracellular
control produced 1.5 pmol per 5 x 106 cells of 7,8-NP whereas cells treated with
IFN-  only produced 0.1 pmol per 5 x 106 cells. This is somewhat unusual at the
IFN-  treatment would be expected to have the same level of 7,8-NP, if not more,
than the amount in the control. As the amount of total pterin produced is the same in
both treatments, it appears that the 7,8-NP produced in the IFN-  treatment has been
oxidized to neopterin. In the supernatant, HMDMs incubated with IFN-  produced
16.5 nM of 7,8-NP compared to 14.6 nM in the control. This slight increase in 7,8-NP
production is not statistically significant. In essence, the addition of 100 U/mL IFN- 
had no effect on pterin production in HMDM cells over 24 hours. However, HMDMs
treated with both IFN-  and cholesterol crystals showed higher intracellular production
of 7,8-NP (10.3 pmol per 5 x 106 cells compared to 1.5 pmol per 5 x 106 cells in the
control). HMDMs incubated with only cholesterol crystals also produced more 7,8-NP
than the control (9.5 pmol). It appears that the introduction of cholesterol crystals
either by itself or in the presence of IFN-  has elicited an inflammatory response from
HMDM cells. Whilst treatments containing cholesterol crystals showed higher 7,8-NP
production, neopterin levels in these samples were lower than the control (8.2 pmol
per 5 x 106 cells in the control, 2.8 pmol for cells incubated with a combination of
IFN-  and cholesterol crystals, and 5.7 pmol per 5 x 106 cells for cells incubated
with cholesterol crystals alone). Cholesterol crystals appear to not only modulate the
balance of 7,8-NP/neopterin, which suggests an oxidative stress, but also increase the
total level of pterin production in the cell, indicating inflammation.
The extracellular fraction has a very similar pattern of neopterin and 7,8-NP
production to the intracellular fraction. One notable difference is that neopterin levels
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in the cholesterol crystal containing samples are higher than in the control (34.3 nM
in the IFN-  and cholesterol crystal sample, and 29.5 nM in the cholesterol crystal
sample compared to 9.5 nM in the control sample). HMDMs treated with cholesterol
crystals produced the most 7,8-NP (27.1 nM) whereas the control cells produced the
least (14.6 nM). Cells treated with IFN-  and a combination of IFN-  and cholesterol
crystals produced 16.5 nM cells and 24.5 nM, respectively.
It is clear from these results that 100 U/mL of IFN-  is not enough to induce
significant 7,8-NP or neopterin production in HMDM cells over 24 hours.
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(a) Intracellular NP and Total Pterin in HMDMs after 24 hours
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(b) Extracellular NP and Total Pterin in HMDMs after 24 hours
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Figure 4.4: Neopterin and Total Pterin measurements in HMDMs after 24 hours.
HMDMs (5 x 106 cells/mL) were incubated at 37  C in RPMI 1640 with 5 mg/mL of
cholesterol crystals and 100 U/mL IFN-  for 24 hours. Controls were conducted in the
absence of cholesterol crystals and IFN- . HMDMs were analyzed for neopterin and total
pterin (7,8-NP and neopterin) production by HPLC analysis. The graphs are of data from
a single experiment that is representative of three separate experiments. Data are mean
values ± SEM of triplicate measurements. Statistical significance is calculated compared
to control values. Significance is indicated as follows: p0.05 - *, p0.01 - **, p0.001
- ***, p0.0001.
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4.2.2.2 Monocytes
It is hypothesized that cholesterol crystals may modulate pterin production in
monocytes as monocytes are the initial cells that infiltrate the site of inflammation. For
the same reasons as outlined in Section 4.2.2.1, a viability assay was conducted prior
to HPLC analysis. The prestoblue viability assay (Figure 4.5) showed that there was
no viability loss due to experimental conditions or the cholesterol crystals. Again one
of the treatments shows a slight rise in viability. Monocytes treated with IFN-  have
122.7% ± 4.77 viability compared to the control (100% ± 8.38). The other treatments
resulted in a 5 to 10% increase in viability over controls, which was not significant.
The experimental set up for all pterin experiments using monocytes is outlined
below in Table 4.2. Monocytes were incubated with the treatments for 24 hours
before neopterin and total pterin levels were measured both in the supernatant and
cellular fractions. Intracellularly, monocytes failed to produce any detectable levels
of 7,8-NP in the control (Figure 4.6). All pterin produced in the intracellular control
was in the form of neopterin (3.5 pmol per 5 x 106 cells). Monocytes treated with
cholesterol crystals also failed to induce 7,8-NP production. It appears that cholesterol
crystals have had no effect on monocytes as neither 7,8-NP nor neopterin production is
significantly different from the control. By comparison, cells incubated with IFN- 
alone produced 4.96 pmol per 5 x 106 cells of 7,8-NP and cells with IFN-  plus
cholesterol crystals produced 8.25 pmol per 5 x 106 cells. It appears that cholesterol
crystals have a small intracellular effect on monocytes that occurs only in the presence
of IFN- . IFN-  and cholesterol crystals appear to act synergistically, producing
both more 7,8-NP and neopterin than shown by either treatment alone. From the
intracellular results, it also seems that monocytes are more sensitive to IFN-  than
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Figure 4.5: Monocyte cell viability after 24 hours - Monocytes were incubated at 37  C
in RPMI 1640 with 5 mg/mL of cholesterol crystals and 100 U/mL IFN-  for 24 hours.
Controls were conducted in the absence of cholesterol crystals and IFN- . Monocytes
were analyzed for remaining cell viability using PrestoBlue. The graphs are of data from
a single experiment that is representative of three separate experiments. Data are mean
values ± SEM of triplicate measurements. Statistical significance is calculated compared
to control values. Significance is indicated as follows: p0.05 - *, p0.01 - **, p0.001
- ***, p0.0001.
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Table 4.2: Experimental set up for monocyte pterin measurement
Control IFN-  IFN-  + CHC CHC
10,000 U/mL IFN-  0 µL 10 µL 10 µL 0 µL
10 mg/mL CHC 0 µL 0 µL 500 µL 500 µL
10 x 106 cells /mL 500 µL 500 µL 500 µL 500 µL
RPMI 1640 510 µL 500 µL 0 µL 10 µL
Total 1010 µL 1010 µL 1010 µL 1010 µL
HMDMs, as there is a small increase in 7,8-NP production upon stimulation with
IFN-  that is not seen with HMDM cells.
All treatments resulted in significant 7,8-NP production in the extracellular
fraction. This suggests that the intracellular and extracellular processes that are
occurring operate quite differently from one another. Cholesterol crystals alone
produced the highest amount of 7,8-NP at 49.5 nM, followed by IFN-  with cholesterol
crystals (36.0 nM). It seems plausible that the cell may benefit from maintaining
different levels of neopterin and 7,8-NP inside the cell to outside the cell when
cholesterol crystals are present. Treatment with IFN-  resulted in 20.6 nM 7,8-NP
which is significantly higher than the 3.9 nM produced by the control. This is not as
high as expected in cells stimulated with IFN- . There was no significant difference
in neopterin levels in the intracellular fraction, however, in the extracellular fraction
both treatments containing cholesterol crystals produced significantly more neopterin
than the control. Incubating monocytes with IFN-  and cholesterol crystals produced
the most neopterin (43.25 ± 1.25 nM). Cells treated with cholesterol crystals only
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produced 32.89 ± 0.92 nM. This is more than twice that found in the control (12.00 ±
3.10 nM). It appears that cholesterol crystals are capable of inducing pterin production
in monocytes as hypothesized, and that this induction can be increased in the presence
of IFN- .
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(a) Intracellular NP and Total Pterin in monocytes after 24 hours
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(b) Extracellular NP and Total Pterin in monocytes after 24 hours
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Figure 4.6: Neopterin and Total Pterin measurements in monocytes after 24 hours
- Monocytes (5 x 106 cells/mL) were incubated at 37  C in RPMI 1640 with 5 mg/mL
of cholesterol crystals and 100 U/mL IFN-  for 24 hours. Controls were conducted in
the absence of cholesterol crystals and IFN- . Monocytes were analyzed for neopterin
and total pterin (7,8-NP and neopterin) production by HPLC analysis. The graphs are of
data from a single experiment that is representative of three separate experiments. Data
are mean values ± SEM of triplicate measurements. Statistical significance is calculated
compared to control values. Significance is indicated as follows: p0.05 - *, p0.01 - **,
p0.001 - ***, p0.0001.
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As stated earlier, 100 U/mL of IFN-  did not induce the expected rise in 7,8-NP and
neopterin levels in either monocytes or HMDMs. To counteract this, the concentration
of IFN-  was increased to 250 U/mL. Experiments at the new concentration of 250
U/mL were only carried out on monocytes as results from Firth et al. (2008) showed
that raising the concentration of IFN-  to 500 U/mL had little effect on 7,8-NP
production in HMDMs. Figure 4.7 shows the range and average neopterin and total
pterin production of monocytes after 24 hours across 5 separate experiments. The
results from these experiments show that increasing the concentration of IFN-  to
250 U/mL successfully induced the production of 7,8-NP in monocytes. It was noted
during these experiments that whilst the trend of neopterin and total pterin production
was the same, the actual amount of pterin produced were quite variable. Control cells
had very consistent neopterin production which ranged between 13.2 and 19.4 nM
for the 5 experiments. The total pterin produced in the control was slightly more
variable (22.4 - 86.3 nM, median= 32.0 nM). Neopterin for all of the treatments ranged
significantly. This suggests that the variation is not an innate artifact due to the cells,
but is probably due to the experimental treatments or donor specific variables. Cells
treated with IFN-  produced anywhere between 92 and 382 nM of neopterin. After
incubation with IFN-  and cholesterol crystals, a range of 27 to 220 nM of neopterin
was produced. Cells incubated with cholesterol crystals only had a smaller range of
13.68 to 45.96 nM of neopterin. It appears that the response to IFN-  induces the most
variation which may be due to modulation in signal transduction in different batches
of cells.
Figure 4.8 shows the 7,8-NP concentrations produced across the five replicate
experiments. From observation, it seemed that cells that had a higher baseline
production of 7,8-NP where the ones that produced higher levels in the treatments,
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almost as if they were already primed. This may partially explain why the amount
of 7,8-NP is relatively variable across the experiments. Cells treated with cholesterol
crystals and IFN-  produced the largest range of 7,8-NP concentrations (30 - 232 nM)
where as control cells produced the smallest (9.2 - 69.2 nM). Monocytes incubated
with either cholesterol crystals alone or IFN-  alone were also highly variable (14 -
156 nM and 127 - 315 nM respectively). While this variation between experiments is
interesting to note, the fact that the overarch trends of 7,8-NP production are consistent
suggests that this variation may be due to the use of primary cells from different donors,
which may respond to treatments differently. As controls across all of the experiments
are consistent, it would suggest that this is a real cellular effect and not an experimental
artifact.
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Figure 4.7: Range and average extracellular pterin production - Monocytes (5 x
106 cells/mL) were incubated at 37  C in RPMI 1640 with 5 mg/mL of cholesterol
crystals and 250 U/mL IFN-  for 24 hours. Controls were conducted in the absence
of cholesterol crystals and IFN- . Monocytes were analyzed for neopterin and total
pterin (7,8-NP and neopterin) production by HPLC analysis. The graph is of data from
five independent experiments. Data are the mean and range from the five experiments.
Statistical significance is calculated compared to control values. Significance is indicated
as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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Figure 4.8: Average 7,8-NP production - Monocytes (5 x 106 cells/mL) were incubated
at 37  C in RPMI 1640 with 5 mg/mL of cholesterol crystals and 250 U/mL IFN-  for
24 hours. Controls were conducted in the absence of cholesterol crystals and IFN- .
Monocytes were analyzed for neopterin and total pterin (7,8-NP and neopterin) production
by HPLC analysis. The graph is of data from five independent experiments. Data are the
mean and range from the five experiments. Statistical significance is calculated compared
to control values. Significance is indicated as follows: p0.05 - *, p0.01 - **, p0.001
- ***, p0.0001.
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4.2.3 Pterin Production after 48 hours of Incubation with
Cholesterol Crystals
4.2.3.1 Monocytes
Literature results have suggested that monocytes produce their maximal pterin levels
after 48 hours (Bitterlich et al., 1988). To investigate whether the IFN-  and cholesterol
crystals have the same effect on the production of 7,8-NP and neopterin with a longer
incubation, monocytes were left in the treatments for a further 24 hours. Monocytes
showed significantly higher production of both neopterin and total pterin after 48 hours
(Figure 4.9). In previous results (Figure 4.6), it was shown that monocytes produced
no detectable levels of 7,8-NP in the intracellular control. However, after 48 hours
in culture monocytes produced 12.1 pmol per 5 x 106 cells in the control. It appears
that achieving detectable levels of 7,8-NP is a slower process than initially thought.
Similarly, after 24 hours there was no detectable 7,8-NP produced by cells treated with
cholesterol crystals. After 48 hours these cells produced 10.9 pmol per 5 x 106 cells
of 7,8-NP which is similar to the amount produced by the control. This appears to
confirm that on their own cholesterol crystals have no effect on intracellular 7,8-NP
production. The increase to 250 U/mL of IFN-  along with the extra 24 hours of
incubation has resulted in an increase in 7,8-NP from 5.0 to 18.3 and 8.3 to 19.3
pmol per 5 x 106 cells, in cells treated with IFN-  and a combination of IFN-  and
cholesterol crystals respectively. After 24 hours of incubation, only the total pterin
concentration in cells treated with both IFN-  and cholesterol crystals was statistically
significant different from the control value. With the additional incubation time and
increase in IFN-  concentration total pterin levels in the two treatments containing
IFN-  are now significantly different from the control. In the two treatments contain
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cholesterol crystals, the concentration of neopterin produced is significantly different
from the control. It appears that the cholesterol crystals are able to induce an oxidative
stress which results in the oxidation of 7,8-NP to neopterin. The effect of the additional
incubation is even more pronounced in the extracellular fraction. After 48 hours all
treatments were significantly different from the control. Treatment of monocytes with
IFN-  produced the highest amount of neopterin (328.7 ± 10.2 nM). However, the
highest production of 7,8-NP was found in cells treated with IFN-  and cholesterol
crystals (169.2 nM) (Figure 4.9). The additional incubation time has no influenced the
way in which the treatments effect pterin production. It does appear that the rate of
pterin production significantly increases between 24 and 48 hours. This effect of time
on pterin production will be explored in more detail in Section 4.2.4.
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Figure 4.9: Neopterin and Total Pterin measurements in monocytes after 48 hours -
Monocytes were incubated at 37  C in RPMI 1640 with 5 mg/mL of cholesterol crystals
and 250 U/mL IFN-  for 24 hours. Controls were conducted in the absence of cholesterol
crystals and IFN- . Monocytes were analyzed for neopterin and total pterin (7,8-NP and
neopterin) production by HPLC analysis. The graphs are of data from a single experiment
that is representative of three separate experiments. Data are mean values ± SEM of
triplicate measurements. Statistical significance is calculated compared to control values.
Significance is indicated as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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4.2.3.2 Mixed Lymphocyte Culture
In vivo there is a milieu of cytokines, immune cells and other factors. Using a simple
purified monocyte culture removes these other factors to give a clean system. The
benefit to using a clean system is that there are less confounding factors influencing the
results. Unfortunately by using a purified monocyte system, some of the more complex
interactions that would normally occur in vivo can be missed. To address some of these
issues a mixed lymphocyte culture can be used instead of pure monocytes. A mixed
lymphocyte culture contains monocytes as well as T cells and B cells. To investigate
whether the presence of T cells, which are known to produce IFN- , modulate the
production of pterins in cells treated with IFN-  and cholesterol crystals, a mixed
lymphocyte culture was used. The mixed lymphocyte culture was produced in parallel,
using blood from the same donor bag, with the monocyte culture in Section 4.2.3.1 and
the experiments were carried out at the same time so that the results could be directly
compared. The mixed lymphocyte culture resulted in even high levels of neopterin and
7,8-NP production than monocytes after 48 hours. Mixed lymphocyte culture control
cells produced 3 times as much neopterin as monocytes after 48 hours (6.3 ± 0.15
pmol per 5 x 106 cells compared to 2.2 ± 0.08). The effect was not as strong in the
IFN-  and combined IFN-  and cholesterol crystal treatments where a 1.3 and 1.7 fold
increase respectively in neopterin was seen. Intriguingly, cells treated with cholesterol
crystals only showed no change in neopterin production (8.7 ± 1.29 pmol per 5 x
106 cells for mixed culture compared to 8.2 ± 0.89 for monocytes). In the mixed
culture, cells incubated with cholesterol crystals only showed an identical response to
the control cells both intracellularly and extracellularly. Treatment with both IFN- 
and cholesterol crystals resulted in the strongest intracellular response, in terms of
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neopterin and 7,8-NP production. These cells had nearly equal concentrations of
neopterin and 7,8-NP present (30.94 and 34.19 pmol per 5 x 106 cells respectively). In
the extracellular component, IFN-  alone (NP= 482 nM, 7,8-NP= 266 nM), resulted in
a slightly stronger response than IFN-  and cholesterol crystals (NP= 391 nM, 7,8-NP=
247 nM).
These results suggest the presence of T-cells increases the amount of 7,8-NP
produced across both the controls and the treatments. It also appears that the
cholesterol crystal induced oxidation of 7,8-NP to neopterin is not enhanced by the
presence of T-cells, as the amount of neopterin produced intracellularly is consistent
in both monocytes and mixed lymphocyte culture. This suggests that this oxidation is
limited, and is not effected by the amount of 7,8-NP present.
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Figure 4.10: Neopterin and Total Pterin measurements in mixed culture after 48
hours - Mixed lymphocyte culture cells (5 x 106 cells/mL) were incubated at 37  C in
RPMI 1640 with 5 mg/mL of cholesterol crystals and 250 U/mL IFN-  for 48 hours.
Controls were conducted in the absence of cholesterol crystals and IFN- . Mixed culture
cells were analyzed for neopterin and total pterin (7,8-NP and neopterin) production by
HPLC analysis. The graphs are of data from a single experiment that is representative
of three separate experiments. Data are mean values ± SEM of triplicate measurements.
Statistical significance is calculated compared to control values. Significance is indicated
as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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4.2.4 Timecourse of 7,8-NP Production
From the results of previous experiments, it seemed that the length of incubation of
monocytes with the treatments appeared to be having a significant effect on the amount
of neopterin and 7,8-NP produced. To investigate this effect further, monocytes were
incubated with IFN-  and cholesterol crystals for up to 96 hours, with neopterin and
total pterin measured at time points across this incubation. Control cells show a steady
level of baseline production of 7,8-NP over the 96 hour period. The rate of 7,8-NP
production in the control cells is 0.2 nM/hr. It appears that the addition of IFN- 
produces a strong early effect, within the first 24 hours, on 7,8-NP production. For
the first 24 hours, cells treated with IFN-  produce 7,8-NP at 4.25 nM/hr. After 24
hours this slows to 1.04 nM/hr for the remaining 72 hours. Monocytes incubated with
both IFN-  and cholesterol crystals initially have a slower rate of 7,8-NP production
compared to their IFN-  only counterpart. For the first 48 hours 7,8-NP is produced at
1.4 nM/hr, higher than baseline levels but much lower than IFN-  only cells. However,
during the next 48 hours 7,8-NP production is strongly induced at a rate of 5.4 nM/hr.
Cells treated with cholesterol crystals have a rate of 7,8-NP similar to the control cells
(0.33 nM/hr) which is consistent across the whole 96 hour period.
Although there appeared to be no sign of the 7,8-NP production slowing in the
IFN-  and cholesterol crystal treatment, the experiment was not taken any further as
cell death would have begun to occur. It appears that the period of incubation does
effect the pterin production in monocytes. Cholesterol crystals appear to be able to
inhibit the production of 7,8-NP due to IFN-  stimulation. However, this inhibition
only occurs for the first 48 hours, after which significant 7,8-NP production takes place
in these cells.
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Figure 4.11: Monocyte 7,8 NP production over 96 hours - Monocytes were incubated
at 37  C in RPMI 1640 with 5 mg/mL of cholesterol crystals and 250 U/mL IFN-  for
up to 96 hours. Control cells were measured in the absence of cholesterol crystals and
IFN- . The graphs are of data from a single experiment that is representative of three
separate experiments. Data are mean values± SEM of triplicate measurements. Statistical
significance is calculated compared to control values. Significance is indicated as follows:
p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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4.2.5 Modulation of Pterin Production in Monocytes by 7,8-NP
Many of the previous experiments seem to suggest that cholesterol crystals cause an
oxidative stress which results in the oxidation of 7,8-NP to neopterin. To test this,
monocytes were incubated with exogenous 7,8-NP for 48 hours. The addition of 200
µM of 7,8-NP resulted in the presence of significant amounts of 7,8-NP in supernatant
of cells treated with IFN-  and in the cell only control (Figure 4.12). There was
very little 7,8-NP found in the supernatant of cell in treatments containing cholesterol
crystals. Monocytes incubated with IFN-  and cholesterol crystals had 0.096 µM of
7,8-NP present in the supernatant while monocytes treated with cholesterol crystals
only had 0.601 µM of 7,8-NP. Compared to the 5.469 µM of 7,8-NP in the control,
these values are insignificant. The cell free control showed that the presence of
cholesterol crystals alone does not cause the total loss of 7,8-NP. The presence of
cholesterol crystals did cause the oxidation of some of the 7,8-NP to neopterin. This
oxidation was also seen in the cell free 7,8-NP only control (data not shown), which
suggests that during the 48 hour incubation some of the 7,8-NP spontaneously oxidizes
to neopterin. Interestingly, monocytes treated with both cholesterol crystals and IFN- 
produced the least amount of neopterin (0.034 µM over control) compared to the other
treatments (0.071 µM over control for cholesterol crystals only and 0.102 µM over
control for IFN-  only).
It appears that in the presence of monocytes and cholesterol crystals, 7,8-NP is
not oxidized to neopterin but instead may be converted to 7,8-dihydroxanthopterin
(7,8-DXP) or its derivative xanthopterin (XP). Cholesterol crystals may be able to
induce a small amount of oxidation of 7,8-NP to neopterin, as seen in previous
experiments, but on a larger scale it appears that this does not occur.
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Figure 4.12: Pterin production in monocytes after addition of extracellular 7,8-NP -
Monocytes (5 x 106 cells/mL) were incubated at 37  C in RPMI 1640 with 5.0 mg/mL of
cholesterol crystals and 250 U/mL IFN-  for 48 hours. 7,8-NP (200 µM) was added to
all treatments prior to incubation. Controls were conducted in the absence of cholesterol
crystals and IFN- . The graphs are of data from a single experiment that is representative
of three separate experiments. Data are mean values ± SEM of triplicate measurements.
Statistical significance is calculated compared to control values. Significance is indicated
as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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4.2.6 Production of IL-1  by Monocytes
It has been found that cholesterol crystals cause the upregulation of IL-1  via the
activation of the NLRP3 inflammasome (Duewell et al., 2010). It is unknown whether
pterins have a role in modulating inflammasome activation and expression of IL-1 
as 7,8-NP has been shown to be involved in the downregulation of proteins such as
CD36 (Gieseg et al., 2010). To investigate the effect of 7,8-NP on IL-1  production in
monocytes, the supernatant from cells was assayed by ELISA.
Treating cells with cholesterol crystals increased IL-1  production after 24 hours
as expected (Figure 4.13a). This effect was heightened by the combination of IFN- 
and cholesterol crystals. The addition of 7,8-NP had no effect on IL-1  levels in
samples without cholesterol crystals. In samples with cholesterol crystals there is a
slight increase in IL-1  levels, however this difference is not statistically significant
when compared to the amount of IL-1  produced by cells in the absence of 7,8-NP.
This production of IL-1  is significantly different from the control which indicates that
the combination of cholesterol crystals and 7,8-NP can modulate IL-1  production in
monocytes.
After 48 hours, the effect of 7,8-NP on IL-1  production is reversed (Figure
4.13b). Cells which had 7,8-NP present show a lower amount of IL-1  than cells
without. This difference between the presence and absence of 7,8-NP is statistically
significant in the cholesterol only treatment. The combination of IFN-  and cholesterol
crystals results in the highest concentration of IL-1  (2.3 ng/mL in the 7,8-NP free
sample compared to 0.74 ng/mL in the control). The treatment of cells with cholesterol
crystals only produced significant amounts of IL-1  when compared to the control.
This was slightly lower than the IFN-  and cholesterol treatment at 2.1 ng/mL.
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It appears that 7,8-NP does have an effect on IL-1  production that is time
sensitive. The ability of 7,8-NP to modulate IL-1  levels may be part of a feedback
loop, as IL-1  has been shown to upregulate 7,8-NP production.
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Figure 4.13: Production of IL-1  by monocytes- Monocytes (5 x 106 cells/mL) were
incubated at 37  C in RPMI 1640 with 5 mg/mL of cholesterol crystals and 250 U/mL
IFN-  for 48 hours. In the treatments containing 7,8-NP, 200 µM was added prior to
incubation. Controls were conducted in the absence of cholesterol crystals and IFN- .
The graphs are of data from a single experiment that is representative of two separate
experiments. Data are mean values ± SEM of triplicate measurements. Statistical
significance is calculated compared to control values. Significance indicated by a bracket
is calculated between samples in the absence and presence of 7,8-NP. Significance is
indicated as follows: p0.05 - *, p0.01 - **, p0.001 - ***, p0.0001.
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5.1 Limitations of Giant Cell Culture for Experimental
Purposes
McNally and Anderson (1995, 2003), among others, have shown that FBGC can
be cultured in vitro using IL-4 and ↵-TocH. However, a clear distinction must be
made between the ability to culture cells and the development of a model system
for experimental purposes. It is known that when using primary cells, up to 20%
of the experimental variation can be accounted for by inter-donor differences (personal
communication). Even taking this known source of variation into account, giant cell
cultures were much more variable in nature than HMDM cultures.
Macrophage cell culture is a technique that has been refined over many decades and
is commonly used by many laboratories. It is much simpler and better understood than
giant cell culture. Successful macrophage culture has two main requirements. The
requirements are attachment of monocytes to the culture surface and differentiation
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from monocytes into macrophages. These two processes can be easily controlled
through the use of specialized adherent tissue culture plates and a bolus introduction
of a differentiation promoting growth factor, such as GM-CSF, at the time of plating.
In contrast, much less is known about the processes that govern giant cell
formation. Giant cell culture is only performed by a small number of research groups
and is a relatively recent development.
5.1.1 Giant Cell Culture and Quantification
It was intended that the giant cells would be cultured in as similar a manner to
macrophages as possible to limit the number of factors that could influence differences
between the cell types. It was hoped that by maintaining analogous culture conditions
it would enable direct comparison of the function and pterin production of these
two cell types. This put constraints on techniques that could be used. HMDM cell
cultures are carried out in Nunc brand plates designed for the culture of adherent cells
using a proprietary surface technology made from modified resins. A recent paper
has highlighted the importance of the variety of cell culture plate used. McNally
and Anderson (2011) found that giant cells grow best on plates containing RGD
peptides which are composed of L-arginine, glycine and L-aspartic acid. RGD peptides
are a recognition sequence used by integrins, the proteins used in cellular adhesion
(Ruoslahti, 1996). Plates that contain RGD peptides are able to mimic the conditions
commonly associated with a foreign body in vivo. This may explain why it was often
observed that giant cells would form on Nunc cell culture plates, but failed to adhere
completely. This failure to adhere meant that during wash steps during techniques such
as staining, the giant cells would often detach from the plate.
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Brodbeck et al. (2005) found that mixed lymphocyte culture, a combination of
monocytes, B cells and T cells, significantly improves the rate of macrophage adhesion
and fusion. A mixed lymphocyte culture, as part of the giant cell culture, was
maintained by direct plating into 12 well plates in the presence of 10% human serum.
Direct plating in the presence of serum prevents the death of the T and B cells that
usually occurs in the absence of serum. However, Brodbeck et al. (2005) initially
plated cells in 20% serum and then subsequently increased to 40% serum. It appears
that this may explain the low adhesion of giant cells observed even in the presence of
mixed lymphocytes.
It appears that the addition of IL-4 aids in the formation of FBGC by activating
the JAK/STAT pathway which leads to the binding of cell to a surface (Varin
and Gordon, 2009). This activation leads to the upregulation of DC-STAMP and
E-cadherin (Mantovani et al., 2007; Moreno et al., 2007). HMDMs treated with
IL-4 showed higher than baseline rates of fusion (Figure 3.4), however, they did not
appear to produce many lamellipodia. Macrophages treated with ↵-TocH did produce
lamellipodia and had a higher percentage of fusion than cells with IL-4. Not only
is ↵-TocH able to induce PS flipping, it is also able to stabilize the lipid bilayer in
a non-asymmetrical arrangement through interactions with arachidonyl and linenoyl
residues within membrane phospholipids (Azzi et al., 2004; Diplock, 1983; Lucy,
1972). Usually, PS exposure would result in an apoptotic response. For example, in
monocyte-like THP-1 cells PS exposure in response to oxLDL coincides with caspase
activation (Baird et al., 2004). Cell death was not observed in the giant cell cultures
(data not shown), which suggests that the cells were expressing the necessary signals
to prevent efferocytosis, that is apoptotic cell removal, by another cell. These same
signals that prevent clearance lead to the fusion of macrophages.
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5.1.2 Fusion
The area of giant cell research is highly focused on the fusion mechanisms of these
cells, as many of the processes leading to fusion are still unknown. In that context it
is not surprising that very few groups have attempted to culture giant cells to model
a disease condition. This thesis attempted to culture and quantify giant cells in a way
that they could be used to model the foreign body response. From the results in this
thesis (Table 3.1), it appears that ↵-TocH is more potent than IL-4 in inducing giant
cell formation. This result differs from that found by McNally and Anderson (1995).
It appears that RGD peptides, mimicking the presence of a foreign body, and IL-4 in
concert are able to potently induce FBGC formation. This would suggest the key step
in facilitating FBGC formation is the ability to form lamellipodia than reach out to
other macrophages. ↵-TocH is then able to mediate cell-cell recognition through the
bind of PS to the CD36 receptor, which in the presence of other signals (e.g. CD47),
leads to cell fusion. In light of what is known about the mechanism of giant cell fusion,
it makes sense that the highest rates of fusion were achieved in the presence of both
IL-4 and ↵-TocH (Figure 3.5). Whilst it was possible to form giant cells, the actual
rate of fusion even with high concentrations of fusion factors was relatively low. The
maximum rate of fusion achieved in this thesis was 29.1%. Rates of fusion reported
in the literature are quite variable. Helming et al. (2009) reported approximately 20%
fusion in the presence of IL-4 and GMCSF. However, under similar conditions using
IL-4 and GMSCF,McNally and Anderson (1995) reported 75% fusion. Vignery (2008)
obtained 50% fusion after 18 days of culture with M-CSF and RANKL. Perhaps one
reason the rates of fusion achieved in Table 3.1 were so low was that they were
measured using a different technique to some of the other studies. Most studies
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solely aim to quantify macrophage fusion, so use techniques such as nuclei staining
(MacLauchlan et al., 2009) or colocalization of fluorescent tags (Jay et al., 2010). As
the cells were intended to be used for further work, staining the nuclei, which involves
fixing the cells, was not a viable technique. Instead the percentage fusion is quantified
by the number of giant cells present in the culture compared to the total number of
macrophages and giant cells present. The seminal paper on macrophage fusion induced
by IL-4 used a similar technique of counting the percentage of multinucleated giant
cells formed and reported a fusion rate of 13% after 5 days (McInnes and Rennick,
1988).
Previous studies (Hicks, unpublished) suggested using giant cells for experiments
from day eight onwards. However, very few giant cells had formed at this point,
and often did not display typical giant cell phenotypic features, such as cytoplasmic
spreading. One benefit to using early giant cells is that since they maintain much
of their macrophage-like morphology, they are very easy to visualize (Figure 3.1).
If giant cells are used at a later stage of development they have lost most of
their macrophage like features. As cytoplasmic spreading occurs, the cells become
increasingly thin. This makes the cells particularly difficult to detect on the plate
(Figure 3.3).
5.1.3 Cell Viability
McInnes and Rennick (1988) measured the effect of IL-4 on the viability of
non-adherent cells in mice bone marrow macrophage cultures, but did not measure the
viability of the adherent giant cells which formed in the same cultures. The adherent
nature of the giant cells limits the options of viability assays available to use. When
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using non-adherent cells, it is possible to take a small sample of cells from the treatment
to test viability. In adherent cultures, the viability assay must be carried out directly in
the well, which generally prevents any further use of that well.
Healthy giant cells were unable to produce enough of the MTT formazan crystal to
be accurately detected by spectroscopy (Figure 3.6). Giant cells have been shown to
have lower succinate dehydrogenase activity than normal macrophages (Papadimitriou
and Wyche, 1976) which will affect their ability to reduce MTT and produce formazan
crystals. Trypan blue staining provided a relatively accurate measure of giant cell
viability (Figure 3.8). Unfortunately, trypan blue exclusion is one of the more time
consuming methods of measuring viability, particularly in adherent cells. Trypan blue
staining was most successful at measuring giant cell viability during the first week of
culture. After this time, the cytoplasmic spreading took place, which made healthy
giant cells much more prone to staining with trypan blue (data not shown). Sone et al.
(1981) found that the giant cell membrane is more ruffled and convoluted than HMDMs
which means that trypan blue become trapped between the folds of the membrane.
This gives the appearance of trypan blue staining, however, the stain has not actually
penetrated the membrane.
With the techniques available, it appears that giant cells cannot be cultured in the
same manner as monocytes or macrophages. This makes a direct comparison between
the cell types problematic. Part of the problem is that this model does not reflect in vivo
conditions. Giant cells in the body only form when a stimulus is present. However,
here we were attempting to induce giant cell formation in the absence of a foreign
body.
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5.1.4 Absorption of Cholesterol Crystals
Small cholesterol crystals (< 10 µm) can be absorbed by macrophages, but large
cholesterol crystals induce a foreign body response (Warren and Yales, 1976). It
appears that mature giant cells are less able absorb cholesterol crystals than HMDMs
(Figure 3.10). The absorption of foreign objects is a complex process which requires
specific receptors to mediate the recognition and uptake of the object. From this
experiment, it appears that cholesterol crystal absorption does not occur due to giant
cell formation, rather that giant cell formation occurs in response to the presence
of cholesterol crystals. It would make sense that mature giant cells that do not
contain cholesterol crystals lose the ability to absorb cholesterol crystals, as it has
been suggested that once the cholesterol crystal has been resolved, the giant cell is also
removed (Luttikhuizen et al., 2006). Giant cells are the end stage of differentiation in
the monocyte lineage (Cohen et al., 1988) and appear to have lost many of the features
that characterize monocytes and macrophages. The timing of giant cell culture is very
important as the age of the monocytes will dramatically impact the ability of the cells
to fuse (Mo¨st et al., 1997). Typically, giant cell formation occurs in the presence of a
foreign body and requires specific mechanisms to occur.
Whilst is it possible to force cells into the foreign body giant cell phenotype, it
is difficult to know whether these cells behave in the same way as those that have
formed in the presence of a stimulus. Monocytes incubated with cholesterol crystals
for seven days began to show features typical of giant cells such as lamellipodia (data
not shown). For that reason, studying the effect of cholesterol crystals on pterin
production in macrophages and monocytes is in some ways more relevant in terms
of modelling the FBR.
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5.2 Modification of Pterin Production by Cholesterol
Crystals in Monocyte-derived Cells
5.2.1 Modification of Pterin Production by Cholesterol Crystals
The effect of cholesterol crystals on pterin production has not been studied before,
which means there is no benchmark or expected response to compare with.
Cholesterol crystals appeared to have a dose-dependent effect on 7,8-NP production in
macrophages (Figure 4.1). Interestingly, this effect was only seen in the intracellular
fraction. This could potentially be explained by the fact that cholesterol crystals seem
to only cause inflammation through activation of the inflammasome (Freigang et al.,
2011). Perhaps it is the uptake of the cholesterol crystals that sets off intracellular
processes such as the production of IL-1  which may lead to the induction of 7,8-NP.
Cholesterol crystals stimulate significant 7,8-NP production in macrophages
(Figure 4.4), however, when this is compared to neopterin production in monocytes
(Figure 4.8) this production is quite small.
One problem of working with primary cells is differences due to donor variation
(figure 4.7). Neopterin and 7,8-NP production was measured in batches of monocytes
from different donors. Batches with a high baseline 7,8-NP production in the controls
produced much higher quantities of 7,8-NP when stimulated (Figure 4.8).
5.2.2 Pterin Production in Monocyte-derived Cells
It was surprising to find that monocytes were much more sensitive to modulation of
7,8-NP production by both IFN-  and cholesterol crystals than macrophages. It was
assumed that macrophages, as more mature cells would produce higher quantities
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of neopterin and 7,8-NP. This suggests a role for monocytes in the initiation of
inflammation. It is unknown why monocytes produce so much more 7,8-NP than
macrophages. It is interesting that this difference is apparent at 24 hours, a point
where macrophages have reached their maximum neopterin and 7,8-NP production,
but monocytes have not.
It was found that the presence of cholesterol crystals causes an inhibition of pterin
production in monocytes and mixed lymphocyte culture cells (Figures 4.9 & 4.10).
It was surprising to find that cholesterol crystals alone are able to induce a small
amount of neopterin and 7,8-NP as generally IFN-  is thought to be the main stimulus
of GTPCH-1 activity. Plu¨ss et al. (1996) were able to show that IL-1  causes a
dose-dependent increase in GTPCH-1 mRNA in mesangial cells, a type of smooth
muscle cell found around blood vessels. The presence of cholesterol crystals seemed
to mediate the effect of IFN- . Cells treated with both IFN-  and cholesterol crystals
were unable to produce the same amount of neopterin or 7,8-NP as cells treated with
IFN-  alone. As monocytes incubated for 48 hours were able to produce more 7,8-NP
than cells incubated for 24 hours, this effect appeared to be time-dependent. To further
explore this a 96 hour timecourse was carried out.
The 96 hour timecourse (Figure 4.11) confirmed that the inhibition of 7,8-NP
production in monocytes was not a total inhibition. Rather the presence of cholesterol
crystals caused a delay or lag phase for the first 48 hours. However, after this time point
monocytes produced more 7,8-NP than seen in cells treated with IFN- . This increase
in 7,8-NP is very significant as it has been found that 7,8-NP acts as an antioxidant
once it reaches µM levels (Gieseg et al., 1995). Recent studies within the Free Radical
Biochemistry laboratory at the University of Canterbury have found that IFN-  was
able to stimulate 7,8-NP production in cells within excised plaque sections (personal
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communication). This suggests that recently recruited monocytes may have a key role
in providing antioxidant protection within the atherosclerotic plaque.
5.2.3 Modulation of Pterin Production by the Addition of 7,8-NP
In order to explore why cholesterol crystals appeared to inhibit 7,8-NP production
within the first 48 hours, cells were incubated with 200 µM of exogenous 7,8-NP
(Figure 4.12). In the presence of cholesterol crystals, by 48 hours all of the exogenous
7,8-NP had been removed. Most unusual was that it was not oxidized to neopterin,
as had occurred in some of the previous experiments. It was thought that this could
be a direct interaction of cholesterol crystals with the 7,8-NP, however, this loss of
7,8-NP failed to occur in the absence of cells. It is highly unlikely that this amount of
7,8-NP could have been taken up by the cells, which suggests that this is most likely an
extracellular process. Also, as the 7,8-NP is not phosphorylated it could not proceed
down the BH4 pathway. Furthermore, 7,8-NP is known to be involved with the folate
biosynthesis pathway, however this pathway is not present in human cells. It is most
likely that the exogenous 7,8-NP has been converted to 7,8-DXP or its derivative XP
which cannot be directly detected at these concentrations by HPLC. The presence of
ROS can induce this conversion of 7,8-NP to 7,8-DXP and XP (Biondi et al., 2012;
Gieseg et al., 2008).
5.2.4 IL-1  Production in Monocytes and Modulation by 7,8-NP
Inflammasome activation by cholesterol crystals has been shown to induce IL-1 
production Rajama¨ki et al. (2010). As expected, cells incubated with cholesterol
crystals produced more IL-1  than the control (Figure 4.13a). Incubating with both
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IFN-  and cholesterol crystals had a synergistic effect on IL-1  production. This was
further enhanced by the presence of 7,8-NP. The addition of 7,8-NP had no effect on
IL-1  in the absence of cholesterol crystals.
By 48 hours (Figure 4.13b) the effect of 7,8-NP on IL-1  is reversed, with less
IL-1  found in the presence of cholesterol crystals and 7,8-NP.
Bauernfeind et al. (2009) found that priming of monocytes was a requirement for
inflammasome activation by crystalline material. They found that monocytes deficient
in interleukin-1 receptor-associated kinase 4 (IRAK4), a protein kinase downstream of
TLR4 and myeloid differentiation primary response protein 88 (MyD88) were unable
to induce caspase-1 activation. The results in this thesis seem to support the possibility
of a single stimulus causing inflammasome activation, as increased IL-1  levels were
seen in cells given only cholesterol crystals. To confirm this hypothesis, it would need
to be proven that the IL-1  production was only due to inflammasome activation.
It is known that the activation of IL-1  can cause a fever (Duff, 1985). Body
temperature can often reach close to 40  C during a fever (Pettigrew et al., 1974).
This may play a role in the resolution of cholesterol crystals as it has been shown
that cholesterol crystals will re-solubilize at this temperature (Geng et al., 2003).
Cholesterol embolization is often accompanied by a fever (Saric and Kronzon, 2011).
5.3 Mechanisms of Cholesterol Crystal Induced
Modification of Pterin Production
Cholesterol crystals appear to induce inflammasome activation, seen as an increase in
IL-1  levels, and potentially produce ROS in monocytes. As well as being implicated
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in these roles, cholesterol crystals also appeared to modulate pterin production. It is
unknown how cholesterol crystals are able to influence pterin production. In most cells
the conversion of GTP to 7,8-NP-PPP is the rate limiting step in the BH4 pathway. It
has been found that the addition of IFN-  causes up to a 40 fold increase in GTPCH-1
activity (Werner et al., 1990).
Monocytes and macrophages produce higher levels of neopterin and 7,8-NP than
other cells as the are deficient in the enzyme PTPS. This deficiency prevents the flow
of 7,8-NP-PPP down the BH4 synthesis pathway. It has been found that blood derived
cells are able to produce the mRNA transcript for PTPS, however, a number of the
transcripts are truncated due to the skipping of exon 3 (Leitner et al., 2003). These
truncated transcripts are unable to produce functioning PTPS. Not all of the mRNA
transcripts encounter this problem so a low level of functioning PTPS is produced.
The presence of IL-1  induces the transcription of PTPS, so purely by shear volume,
it is likely that more functioning PTPS is produced (Franscini et al., 2003).
5.4 Role of Cholesterol Crystals and Foreign Body
Giant Cells in Atherosclerosis
Cholesterol crystals have been shown to induce inflammation and can be particularly
dangerous when present in atherosclerotic plaques. Cholesterol crystals may cause
erosion of the fibrous cap and rupture of the necrotic core in plaques (Abela, 2010;
Michel et al., 2011). If the plaque ruptures, hemorrhage can occur. Cholesterol
crystals exposed to the blood form emboli which can block blood flow (Flory, 1945;
Moolenaar and Lamers, 1996). Katz et al. (1982) found that there was a very low
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Figure 5.1: Modulation of pterin production by IL-1  - The enzymatic conversion of
GTP to 7,8-NP-PPP is strongly induced by IFN-  and to a lesser extent by IL-1 . IL-1 
causes the upregulation of the enzyme PTPS that converts 7,8-NP-PPP to 6-pyruvoyl
tetrahydropterin. IFN-  is able to upregulate PTPS as well, but not to the same extent
as IL-1  .Adapted from Franscini et al. (2003)
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turnover of cholesterol crystals in plaques by studying the lipid composition. Small
(1988) confirmed this result using a primate model. Both Katz et al. (1982) and Small
(1988) suggest that this low turnover may prevent plaque regression.
The presence of multinucleated cells in human atherosclerotic plaques has been
confirmed by both transmission electron and scanning microscopy of samples taken
from post-mortem subjects (Tokunaga et al., 1989). FBGC are thought to form in
plaques in order to resolve cholesterol crystals. It has been found that giant cells release
matrix metalloproteinase-9 (MMP-9) which is involved in matrix degradation (Boyle,
2005; Rittner et al., 1999). This is thought to add to plaque instability and inflammation
through remodelling of the fibrous cap (Zhu et al., 2007).
5.5 Future Research
The role of cholesterol crystals and the FBR is a largely unresearched area. In
particular, there has been very little study into pterin production as a result of
cholesterol crystals. Continuing from the work in this thesis, further study on how
cholesterol crystals modify pterin production, would develop the understanding of
the role of cholesterol crystals in atherosclerotic plaques. It would be especially
informative to study how cholesterol crystals caused the total loss of exogenous
7,8-NP. Clearly, this process is cell mediated and does not involve the oxidation of
the 7,8-NP to neopterin.
Another area which has yet to be fully explored is the type of inflammatory
response that cholesterol crystals induce. It would be interesting to know if cholesterol
crystals add to the atherosclerotic burden through the stimulation of the production
of ROS. Shen and Blair (2006) found that cholesterol crystals interfere with flow
106
5.6 Summary
cytometry, the technique commonly used to quantify oxidative stress. However,
ROS production could be measured by a dihydroethidium (DHE) stain which can be
quantified by fluorescence microscopy.
Furthermore, additional study may confirm the production of BH4 in monocytes
due to cholesterol crystals. According to the currently known mechanisms, BH4
production is likely to be increased in the presence of cholesterol crystals. Often BH4 is
indirectly measured through an assay which quantifies NO production as BH4 is a NOS
cofactor. However, it has been shown that IL-1  can directly increase NO production
through NF-B transcriptional regulation of NOS (Kwon et al., 1995). This would
need to be considered when designing an experiment to measure BH4 production.
5.6 Summary
Foreign body giant cells play an important role in the resolution of the foreign body
response in vivo. The resolution of cholesterol crystals has the potential to lessen
inflammation in the atherosclerotic plaque and aid in limiting disease progression.
For this reason, understanding the modulation of inflammatory processes such as the
production of pterins in monocyte derived cells by cholesterol crystals is important.
Cholesterol crystals also provide a potential target in atherosclerotic plaques for newly
developed imaging technology and may be able to act as an indirect measure of the
level of disease progression.
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